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Introduction  
 
     Natural products provides research opportunities deriving from its biological properties. 
Some efforts direct toward the synthesis of agents regarding the structure of the natural product, of 
which structure has served as the basis for the design of several new classes of drugs saving 
thousands of lives not only humans also animals.  
     Needless to say, natural products have complicated structure, including members of 
aminoglycoside, macloride, tetracycline, and β-lactam antibiotics. In addition to such antibiotics, all 
natural products have beautiful and atractive structure. In the past century, their structure have been 
assigned by nuclear magnetic resonance (NMR), infrared spectroscopy (IR), and mass spectrometry 
(MASS). Recently, spectroscopic abilities have developed and they contribute structural elucidation 
in any cases, of course, mistakes are still a common occurrence despite the present advantages. On 
the contrary, it is amazing just how many complicated natural products have been assigned 
correctly, especially when only limited material was available or the natural substance in question 
was unlike any other ever observed.  
     Highly oxidized structures have been observed in nature such as (–)-tetrodecamycin, (+)-
actinopyrone A, TMC-264, and they would be also led to new class of drugs. Thus, their structure 
should be guaranteed to use as chemotherapeutic agents. Generally, highly oxidized and highly 
substituted products have less information to analyze by 1H-NMR and would be faced to difficulty 
of structural determination. Sometimes 13C-NMR or X-ray crystallographic analysis make up for 
the lack of 1H-NMR information. In addition, their high reactivity causes decomposition of 
themselves. 
     This dissertation would like to present the total synthesis and structural determination of these 
three significant natural products. Natural products whose originally proposed structures have been 
guaranteed by total synthesis, considering certain stereocenter and clear construction of their 
structure. Thus, the total synthesis is efficient tool to guarantee the structure of natural products.  
Indeed, structural determination clearly provide opportunities for synthetic chemists to make 
discoveries through total synthesis, and certainly show that there is still adventure to be had in the 
process of structure assignment. Moreover, the total synthesis of natural products has served as the 
flagship of chemical synthesis and the principal driving force for discovering new chemical 
reactivity, evaluating physical organic theories, testing the power of existing synthetic methods, and 
enabling biology and medicine. 
 
 
      In chapter 1, I describe the first total synthesis of (–)-tetrodecamycin, isolated in the course 
of screening program for novel antimicrobial antibiotics against Pasteurella piscicida, causing fish 
diseases known as pasteurellosis. The synthesis of structurally complex (–)-tetrodecamycin has 
required numerous examination to construct the tetracyclic core especially 7-membered ring and 
following tetronic acid core. Thus, this research have lasted twelve years in our laboratory. (–)-
Tetrodecamycin has been synthesized from D-(–)-mannitol through stereoselective Michael addition, 
aldol reaction, 1,4-reduction, SmI2-mediated pinacol cyclization, and newly developed 
deoxygenation. 
 
 
 
 
 
 
 
 
－1－ 
     In chapter 2, I describe the first total synthesis of (+)-actinopyrone A, isolated as a relatively 
unstable compound possessing coronary vasodilating activity and antimicrobial activity. Later, it 
was found to exhibit potent anti-Helicobacter pylori activity. The half value period of (+)-
actinopyrone A is 2 weeks at 4 °C in non-solvent and wet solvent, and the unstability would be 
caused by the deconjugated structure. (+)-Actinopyrone A has been synthesized by using our 
developed remote stereoinduction, Kocienski olefination, Horner–Wadsworth–Emmons olefination, 
and reductive de-conjugation of the vinylpyrone. A concise method has also been established by O-
methylation to obtain the γ-pyrone. 
     In chapter 3, I describe the first total synthesis of TMC-264, an inhibitor of IL-4 signal 
transduction, isolated from the fermentation broth of a fungus Phoma sp. TC 1674 and represented 
a new class of antiallergic agents. The fully substituted quinol core of TMC-264 has less 1H-NMR 
information to define the structure. TMC-264 has been synthesized through regioselective 
bromination, selective protection of catechol, and biaryl coupling. 
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Main issue 
 
 
Abbreviation 
 
Ac acetyl PCC pyridinium chlorochromate 
aq. aqueous Ph phenyl 
Bn benzyl PPTS pyridinium p-toluenesulfonate 
Bz benzoyl Pr propyl 
cat. calculated Py pyridine 
COD 1,5-cyclooctadiene quant. quantitative 
CSA 10-camphosulfonic acid TBAC tetra-n-butylammonium chloride 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene TBAF tetra-n-butylammonium fluoride 
DEAD diethylazodicarboxylate TBS tert-butyldimethylsilyl 
DIBAL diisobutylaluminum hydride TFA trifluoroacetic acid 
DME dimethoxyethane THF tetrahydrofuran 
DMF N,N-dimethylformamide TMS trimethylsilyl 
DMSO dimethylsulfoxide Tr triphenylmethyl 
Et ethyl WSCI 1-(3-dimethylaminopropyl)-3-ethyl- 
HMDS hexamethyldisilazide  carbodiimide (water soluble carbodiimide) 
HMPA hexamethylphosphoramide   
IBX o-iodoxybenzoic acid   
IP isopropylidene   
LDA lithium diisopropylamide   
m-CPBA m-chloroperbenzoic acid   
Me methyl   
MOM methoxymethyl   
NBS N-bromosuccinimide   
NCS N-chlorosuccinimide   
NIS N-iodosuccinimide   
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1. Total Synthesis of a Tetracyclic Antibiotic, (–)-Tetrodecamycin. 
 
 
1.1. Introduction 
 
 
     Recently, cultivation of many kinds of fishes is being undertaken extensively worldwide to 
ensure steady fish catches. Fish diseases are among the biggest concerns in fish farming. The fish 
disease caused by a bacterial septicemia, pasteurellosis (pseudotuberculosis), has become a 
considerable economic problem worldwide, inflicting significant losses in the farming industry of 
fishes such as yellowtail, sea bass and sea bream. Prevention of this disease is therefore considered 
an important aspect for the successful culture of fishes.  As far as intenxive fish culture goes, a 
large amount of fish food and antibiotics have been used to increase production and to protect fish 
from diseases. Consequently, a large portion of feeds and antibiotics enters the water as wastes, 
causing water pollution. There exists great concern over the widespread use of antibiotics in 
aquaculture, which may result in residue of antibiotics in water and mud. Therefore it is significant 
task to provide novel agents which has little toxicity. Photobacterium damselae subsp. piscicida is 
well known as the causative agent of the fish disease pasteurellosis, although the organism and the 
fish disease have also been described as Pasteurella piscicida and pseudotuberculosis, respectively. 
In the course of a screening program for novel antimicrobial antibiotics against Pasteurella 
piscicida, the Institute of Microbial Chemistry group has isolated an antibiotic, (–)-tetrodecamycin 
(1), from a culture broth of Streptomyces sp. MJ885-mF8 (Figure 1).1 (–)-Tetrodecamycin (1) has 
been reported to show strong antimicrobial activities especially against Pasteurella piscicida, but no 
toxicity in mice at a dose of 100 mg/kg when administered intraperitoneally.2 
      Various chemotherapeutic agents such as derivatives of tetracycline (2), oxolinic acid (3), 
florfenicol (4), and bicozamycin (5) have been used to treat bacterial infections in cultivated fishes, 
but extensive use has led to an increase in drug-resistant strains among pasteurellosis. Therefore  
(–)-tetrodecamycin (1), which has different structure compared with existing antibiotics, would be 
expected to new classes of antibacterial agent with novel mechanism. Novel mechanisms of action 
are urgently needed, due to the worldwide emergence of infections caused by multidrug resistant 
bacteria. 
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Figure 1. Chemotherapeutic agents for fish diseases. 
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     The structure of (–)-tetrodecamycin (1) was elucidated by nuclear magnetic resonance 
(NMR) studies and X-ray crystallographic analysis to be distinguished by a tetronic acid-containing 
tetracyclic skeleton, the one cyclohexane ring of which is fully and diversely substituted.3  
Moreover, the quaternary carbons are located at C-7 and C-13. The imposing structure and potential 
medicinal importance of this molecule have attracted a great deal of attention from other researchers 
since the disclosure of the structure, although the total synthesis had not been reported until our 
total synthesis.4-10 
     Paintner reported the asymmetric synthesis of key building block, which contains four of the 
six stereogenic centres inherent in (–)-tetrodecamycin (1) (Scheme 1).5 In addition, Paintner also 
has attempted acid catalyzed cyclization of allylic alcohol.6-8 Barriault challenged to synthesize the 
derivatives which had tans-decaline core. They reported the interesting method, in which 
intermediate was rapidly constructed via cascade oxy-Cope/ene/Claisen rearrangement of allylic 
ether to give the trans-decalin core.9,10 Baldwin and Tchabanenko reported an unusual silyl enol 
ether isomerisation followed by an intramolecular Diels–Alder cycloaddition.11 But all they have 
not achieved to the total synthesis of (–)-tetrodecamycin (1). 
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Scheme 1. Toward the total synthesis of (–)-tetrodecamycin (1). 
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1.2. Retrosynthetic Analysis 
 
 
      From the retrosynthetic perspective, we envisioned that the tetronic acid-containing 7-5-
membered core of (–)-tetrodecamycin (1) would be accessible from the aldehyde 6 by a cyclization 
of 7-membered ring followed by lactonization (Scheme 2). We planned an efficient construction of 
6 through the formation of the cis-diol by the SmI2-mediated pinacol cyclization of the keto 
aldehyde 7, which would be stereospecifically derived from lactone 9 through the quaternary 
compound 8. Lactone 9, the starting material such as a cochleamycin synthesised in our laboratory, 
is derived from D-(–)-mannitol (10). 
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Scheme 2. Retrosynthetic analysis of (–)-tetrodecamycin (1). 
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1.3. Stereoselective Construction of trans-Decaline 
 
 
     The synthesis was initiated with establishment of the efficient root to construct trans-decaline, 
which would be the starting material to investigate several conditions for the first total synthesis of 
(–)-tetrodecamycin. Silica gel column chromatography should be avoided to perform the procedure 
in multi gram scale. Therefore, the procedure to prepare the lactone 9, which was well known 
compound as useful starting material, was improved (Scheme 3).   
     In previous our experience, the diacetonide 11 from D-(–)-mannitol (10) was purified by 
silica gel column chromatography. Alternatively, after the reaction was neutralized, only the 
removal of solvent and subsequent oxidative cleavage gave the aldehyde 12. The aldehyde 12 was 
distillated because of unstability on silica gel and low boiling point. Wittig reaction to give α,β-
unsaturated ester 13 was undertaken in MeOH. After removal of MeOH, hexane and Et2O was 
poured into the residue. The α,β-unsaturated ester 13 was soluble in the mixed solvent and Ph3P=O, 
which was generated by Wittig reaction, was almost insoluble. The solid was removed by filtration, 
and the filtrate was concentrated under reduced pressure. This operation was repeated several times. 
After that, a mixture of α,β-unsaturated ester 13 in hydrochloric methanol was followed de-
isopropylidenation and subsequent lactonization gave the α,β-unsaturated lactone 14. Tritylation of 
the α,β-unsaturated lactone 14 was achieved by TrCl and NH4NO3 in DMF.12 When the reaction 
was completed, the reaction mixture was poured into ice water, which dissolved the reagents and 
DMF. Insoluble syrup was left at flask by decantation, thus we avoided the extraction which needed 
a large amount of solvent. It was the first time to purify a compound by silica gel column 
chromatography and lactone 9 was obtained from D-(–)-mannitol (10) in high efficiency (32% in 5 
steps). 
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Scheme 3. 
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     The quaternary product 8 was stereoselectively synthesized from the lactone 9, having S-
configuration (Scheme 4). The lactone 9 was converted into the 2,3-dimethyl derivative 16 by 
Michael addition and following methylation.13,14 Although diastereomeric compounds were 
obtained, the single lithium enolate was prepared to react stereoselectively with cyclohexanone and 
subsequent dehydration gave the quaternary product 8. The structure was confirmed by X-ray 
crystallographic analysis (Figure 2, R factor = 0.0665). 
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Figure 2. X-ray structure of 8. 
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     The first stage of the progression of 8 to (–)-tetrodecamycin (1) involved the further 
development of stereoselective reaction and constructed carbon atom at C-8 (Scheme 5). High 
stereoselectivity was observed by epoxidation with m-CPBA or hydroboration with BH3･THF from 
8, although the stereochemistry was not defined. Reductive opening of the epoxide 18 was not 
reacted smoothly. Additionally, selective protection of the triol 20 was required several steps. Thus, 
the synthetic route was changed because desired compounds were not synthesized efficiently in 
subsequent step. 
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Scheme 5. 
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     The second route, the triol 20 was also tried to obtain from 8 via the α,β-unsaturated ketone 
22, however, the route gave 22 in low yield and the selective protection of triol was found to be 
difficult (Scheme 6). Thus, the construction of carbon atom at C-8 should be constructed after 
selective protections. 
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Scheme 6. 
 
 
     Hydride reduction of 8 to the diol 23 with LiBH4 was successively followed by selective 
protection as the benzyl ether and the tert-butyldimethylsilyl ether to give 24 (Scheme 7).  
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Scheme 7. 
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      The obtained cyclohexene 24 was investigated to construct carbon atom at C-8 with 
introduction of the hydroxy group to C-13 by hydroboration, however, the stereoselectivity was 
unsatisfactory (Scheme 8).  
     Regioselective oxidation of 24 with SeO2 gave the α,β-unsaturated cyclohexenone 27 as a 
single product in 86% yield. The 1,4-reduction of 27 was achieved with NaBH4 in the presence of 
NiCl2•6H2O to give a diastereomeric mixture of 28 and 29 in 77% and 15%,15 respectively. The 
undesired 29 was recycled by epimerization to the desired 28 in alkaline MeOH. The structure of 
28 was also determined by the X-ray analysis (Figure 3, R factor = 0.0357). 
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Scheme 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. X-ray structure of 28. 
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    The stereoselectivity was explained as below. The allylic strain of the α,β-unsaturated 
cyclohexenone 27 would cntribute the desired stereoselectivity to construct the C-8 stereochemistry 
and considering the cyclohexene 24 the stereoselectivity was observed conversely (Figure 4).  
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Figure 4. Allylic strain of α,β-unsaturated cyclohexenone 27 and cyclohexene 24. 
 
 
     Several reducing conditions were examined as described in Table 1. General conditions were 
favored to generate 1,2-reduced form or concomitant 1,2 and 1,4-reduced form. These result 
suggested that combination of NaBH4 and NiCl2･6H2O reacted as other mechanism compared with 
general hydride reduction. The active catalyst NiB2 was generated with NiCl2･6H2O and NaBH4 
under a nitrogen atmosphere. The excess NaBH4 was used to generate hydrogen in MeOH. The 
immediate formation of a black granular precipitate indicated that the catalyst formed.  
 
 
Entry Condition Result and Ratio   
       1,2- 1,2-and 1,4- 
 Reagent Solvent Additive 28 : 29 : reduced form : reduced form 
1 NaBH4 MeOH None 0 : 0 : 0 : 1 
2 Py 〃 〃 Multiple compunds 
3 〃 MeOH-THF CoCl2 1 : 0 : 10 : 0 
4 LiAlH4 THF None 1 : 1 : 2 : 0 
5 〃 〃 CuI 0 : 0 : 1 : 0 
6 LiEt3BH None 1 : 1 : 0 : 2 〃
 
Table 1. 
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     Selective removal of the triphenylmethyl group of 28 was achieved by Et2AlCl (Scheme 9). 
Under the general conditions of de-protection such as 90% aq. AcOH and BF3･Et2O in aq. MeCN 
were observed the silyl migration to primary alcohol. Thus, aluminum protected the primary 
hydroxide in situ under these conditions using Et2AlCl. Subsequent PCC oxidation gave the keto-
aldehyde 7. 
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Scheme 9. 
 
 
     The final stage was settled on the stereoselective construction of trans-decaline. Proposed 
transition states of pinacol cyclization from the keto-aldehyde 7 were illustrated in Figure 5. A 
would be more prefered transition state than B in which the two carbonyl groups was faced contrary. 
C and D would be unstable because of 1,3-diaxial repulsion with cyclohexane ring and methyl. 
Other conformers might be also unstable by 1,3-diaxial repulsion with CH2OBn and OTBS. 
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Figure 5. Transition states of pinacol cyclization from keto-aldehyde 7. 
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     And the keto-aldehyde 7 gave the requisite cis-diol 31 with SmI2 and t-BuOH as a single 
product resulting from the most stable transition state of the chelation-controlled reaction (Scheme 
10).16  
 
     Trans-decaline was established and all stereochemistry would be defined in this stage. 
Therefore, 31 was converted into acetonide 34 via 33. Crystalline 34 was obtained by 
recrystallization from EtOAc. The configuration of 34 was confirmed by the X-ray crystallographic 
analysis as shown in Figure 6 and the R factor was 0.0408. 
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Scheme 10. 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. X-ray structure of 34. 
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1.4. Construction of 7-Membered Ring 
 
 
     Progression toward synthesis of (–)-tetrodecamycin was required two key steps, which were 
acylation at C-6 and oxy-Michael addition to C-3 (Scheme 11). Two routes were envisioned to 
construct 7-membered ring, conveniently named route A, which was acylation and subsequent oxy-
Michael addition, and route B, which was oxy-Michael addition and subsequent acylation.  
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Scheme 11. 
 
 
     Synthesis of (–)-tetrodecamycin was first attempted by route A, and several conditions were 
examined with the acylated 35 (Scheme 12). Under these conditions 1,2-addition subsequent acetal 
formation followed by dehydration occurred. 
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Scheme 12. 
 
     Next, we examined route B, which was shown in following page. 
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      Di-O-methoxymethylation and de-O-silylation of 31 proceeded to give the alcohol 38 
(Scheme 13). Oxy-Michael addition to α,β-unsaturated acetylene derivative with Me3P afforded the 
enol ether 39. This oxy-Michael addition was achieved in high yield, and 39 was lead to various 
derivatives to investigate the construction of 7-membered ring. However, the desired tricyclic 
compound 41 or tetracyclic compound 43 were not obtained (Scheme 13 and 14). Althoug exact 
structure was not determined, a compound reacted at γ-position was observed. Thus, exo-methylene 
group should be introduced and following cyclization. 
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     After the introduction of exo-methylene group, various conditions were examined with 44. 
However, our efforts resulted in disappointment and not to generate the desired tetracyclic 
compound 45 (Scheme 15). 
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Scheme 15. 
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     After numerous examinations, it was reallized that the maleate derivative 46 was converted 
smoothly into the desired 7-membered ring (Scheme 16).  
     Michael addition of 34 to diethyl acetylenedicarboxylate gave a mixture of 46 and 47 in 75% 
and 15% yield, respectively, the stereochemistry of which was determined by NMR studies, 
especially by the chemical shifts of the olefin protons.17 Reductive removal of the benzyl group of 
the desired olefin 46 gave the alcohol, which was oxidized to the aldehyde 6. Treatment of 6 with 
NaHMDS constructed the 7-membered ring to afford a 5:1 diastereomeric mixture of the alcohols 
48, which was oxidized to a single product 49 by IBX oxidation. 
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Scheme 16. 
 
 
     The diastereomeric 48 were separated by silica gel column chromatograhpy and the major 
product was confirmed the structure by HMBC as shown in Figure 7. Correlations between H-6 and 
C-7, H-15 and C-7, H-6 and C-3, H-15 and C-3 were obserbed. 
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Figure 7. HMBC of 48. 
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1.5. Total Synthesis of (–)-Tetrodecamycin 
 
 
     In the diester 49, the C-2 ester is anticipated to be less reactive than the C-3 ester to submit 
reduction because of the tautomerization with the ring oxygen atom. Initial investigations 
contemplated hydride reduction to furnish lactone 50 by reduction and subsequent lactonization. 
However, either ketone or olefin of the diester 49 was reduced, and the desired 50 was not obtained 
(Scheme 17).  
 
O
O
Me
Me
H
O
O
CO2Et
CO2Et
49
O
O
Me
Me
H
O
O
O
O
50
3
2
 
Scheme 17. 
 
 
      We then turned to access saponification which might eventually lead more reactive compound, 
such as the acid chloride 52 or activated ester 53 (Scheme 18). As expected, 49 was selectively 
hydrolyzed to the mono-acid 51. However, several attempts were not directed toward generation of 
50. The reduction of  ketone or olefin were also prefered. 
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Scheme 18. 
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     Our effort reached an implementable solution. The acid 51 was transformed to the thioester 
54, which was reduced under Fukuyama conditions with Et3SiH to the aldehyde with concomitant 
cyclization to the diastereomeric acetal 55 (Scheme 19).18 
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Scheme 19. 
 
 
      General procedures were attempted to deoxygenate the acetal 55 under a variety conditions. 
Two carbonyl substitutes influenced to afford multiple compounds under acidic conditions or by 
radical reduction. Neutral and mild condition was recommended to convert 55 into lactone ring. 
 
     On the other hand, indirect deoxygenation would be anticipated with the acetal 55 and 
bromination was attempted to furnish 57 and subsequent debromination to generate the desired 
lactone 50 (Scheme 20). And fortunatelly this was lead to our newly developed procedures.  
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Scheme 20. 
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     Deoxygenation of the acetal 55 was effected in one operation using CBr4 and PPh3 to furnish 
the lactone 50 by bromination19 followed by debromination20 with PPh3 and subsequent protonation 
(Scheme 21). Deacetonation of 50 with 70% aq. TFA afforded the diol 59, which, upon treatment 
with N,N-dimethylmethyleneammonium iodide (CH2=N+Me2I–),21 underwent introduction of an 
exo-methylene group to give (–)-tetrodecamycin (1).  
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Scheme 21. 
 
 
     This was identical in all respects with the natural product, including spectroscopic 
characteristics (1H and 13C-NMR spectra, and mass spectra) and optical rotation [synthetic 1: [α]D26 
–6.0 (c 0.42, MeOH); natural product: [α]D23 –6.0 (c 0.50, MeOH)], completing the stereoselective 
total synthesis to confirm the absolute structure. 
     In conclusion, trans-decaline was synthesized from D-(–)-mannitol through stereoselective 
Michael addition, aldol reaction, 1,4-reduction, and SmI2-mediated pinacol cyclization. 
Construction of 7-memberd ring was achieved through enol etherification and subsequent acylation. 
Tetronic acid core was established by regioselective hydrolysis, thio esterification, silane reduction, 
and our newly developed deoxygenation effected in one operation using CBr4 and PPh3. Subsequent 
introduction of exo-methylene group gave (–)-tetrodecamycin (1). 
 
 
 
 
 
 
 
 
 
 
 
－21－ 
2. Total Synthesis and Structural Determination of (+)-Actinopyrone A 
 
 
2.1. Introduction 
 
 
     (+)-Actinopyrone A (60) was isolated from Streptomyces pactum S12538 as a relatively 
unstable compound possessing coronary vasodilating activity and antimicrobial activity.22,23 Later, 
it was found to exhibit potent anti-Helicobacter pylori (H. pylori) activity (Figure 8).24 (+)-
Actinopyrone A (60) exhibited potent anti- H. pylori activity with MIC value of 0.0001 (μg/ml). 
     Many recent studies have shown that peptic ulcer diseases are mainly caused by H.pylori 
infection.25,26 Eradiation of this bacterium dramatically decreases the recurrence rate in peptic ulcer 
patients. Treatment regiments including a proton pump inhibitor and antimicrobial agents such as 
amoxicillin (61) and macrolide compound are recommended. Recently some agents are proposed 
such as tatridin-A (62) and CJ-12,954 (63). However, these therapies have problems including side 
effects, build-up of drug resistance, and poor compliance. Therefore the development of a new class 
of anti-H.pylori agents is needed. The instability of (+)-actinopyrone A (60) makes it difficult to 
promote further research. The half value period of actinopyrone A is 2 weeks at 4 °C in non-solvent 
and wet solvent, and the unstability would be caused by the deconjugated structure. Thus, (+)-
actinopyrone A (60) has been required to be established the total synthesis. And multi-bioactivity 
and little toxicity makes 60 to be an attractive candidate of a drug for chemotherapy. 
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Figure 8. Anti-Helicobacter pylori (H. pylori) agents. 
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     The absolute structure of (+)-actinopyrone A (60), especially stereochemistry of C-14 and C-
15, has not been disclosed yet. Thus, we also aim to define the absolute structure by total synthesis. 
     The side chain of (+)-actinopyrone A (60) is similar to piericidin A1 (72), which has been 
synthesized by Boger and co-workers.27 They examined several methods to synthesize the aldehyde 
71, the key intermediate of the side chain, and their best result is shown in Scheme 22. The 
aldehyde 71 was obtained from the oxazolidone 64 in 7 steps and over all yield is 27%. Thus, we 
would investigate to construct the aldehyde 71 by concise method. 
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Scheme 22. The total synthesis of piericidin A1 (72). 
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2.2. Retrosynthetic Analysis 
  
 
     Our previous efforts revealed that any allyl pyrones were unstable, thus 74 and 75 were not 
obtained from 73 (Scheme 23). Therefore, de-conjugated products were recommended to be 
constructed in the final steps. 
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Scheme 23. Our previous synthetic strategy. 
 
    The synthetic plan possessed two significant steps (Scheme 24). They were de-conjugation of 
vinyl pyrone and stereoselctive construction of C-14 and C-15 positions. To avoid instability of (+)-
actinopyrone A (60), the conjugated pyrone 76 was set up as the precursor. The precursor 76 
would be subjected to the reductive de-conjugation of the vinyl pyrone moiety in the final stage of 
the synthesis. The conjugated pyrone 76 might be synthesized by connection of the compounds 69 
and 77-79. The chiral C-14 and C-15 positions should be constructed by the remote stereocontrol 
methodology developed in our laboratory using the chiral vinylketene 77, which was prepared from 
D-valine.28 
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Scheme 24. Retrosynthetic analysis of actinopyrone A (60). 
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2.3. Synthesis of Significant Segments 
 
 
     The epoxy-sulfone 78 was synthesized in 2 steps from the commercially available 80 
(Scheme 25). The alcohol 80 was converted to the tetrazole 82 under Mitsunobu conditions. Both 
olefin and sulfide of 82 were oxidized to give the epoxy-sulfone 78 by treatment with m-CPBA in 
the presence of NaHCO3. 
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Scheme 25. 
 
     During the synthesis of the γ-pyrone moiety 79, we found a concise and economical method 
of O-methylation to convert 4-hydroxy-2-pyrone to 2-methoxy-4-pyrone (Scheme 26). Treatment of 
the known α-pyrone 83 with CaCO3 and Me2SO4 in acetone at 50 °C promoted 2-O-methylation to 
give the γ-pyrone 73 as a major product. The regioselectivity of the O-methylation was 2-O-
methylation/4-O-methylation = 3/1. The isolated yield of the γ-pyrone 73 (56%) is comparable to 
the yield under conditions with MeSO3F (53%).29 The regioselective chlorination of γ-pyrone 73 to 
obtain the chloromethylpyrone 84 was realized with LHMDS and NCS, which was followed by 
substitution with P(OEt)3 to afford the phosphonate 79. 
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Scheme 26. 
 
 
 
 
 
 
 
 
 
 
－25－ 
    Stereoselective construction from C-11 to C-18 unit 71 was achieved by our remote 
stereocontrol methodology (Scheme 27). Coupling of the silyl dienolate 77 and tiglic aldehyde 65 
in the presence of TiCl4 gave C-14 and C-15 anti-adduct 86 as a single isomer. Protection of 86 as 
the TBS ether afforded the crystalline 87, of which stereochemistry was determined to be the 
(14R,15R)-isomer by X-ray crystallography as expected (Figure 9, R factor = 0.0641). The chiral 
auxiliary of 87 was removed to give the aldehyde 71 by treatment with DIBAL at –78 °C.  
     Consequently, the aldehyde 71 was obteined from the oxazolidone derivative 85 in 4 steps 
and over all yield was 47%. Thus, our remote stereocontrol methodology was more efficient to 
prepare 71, compared with known methods illustrated in Scheme 21. 
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Scheme 27. 
 
 
 
            
 
 
 
 
 
 
 
 
 
Figure 9. X-ray structure of 87.  
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2.4. Total Synthesis of (+)-Actinopyrone A 
 
  
    The aldehyde 71 was converted to the triene 88 (10,11-E/10,11-Z = 93/7) by Kocienski’s 
method using the sulfone 78 (Scheme 28).30 The triene 88 was transformed under the acidic 
conditions to the primary alcohol 90, which was separated from 10,11-Z-isomer by silica gel 
column chromatography. The alcohol 89 was submitted to oxidation to afford the aldehyde 90. The 
pyrone moiety was introduced by Horner–Wadsworth–Emmons reaction of 90 with the 
phosphonate 79 to afford the stable vinylpyrone 91. 
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Scheme 28. 
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     De-O-silylation of 91 under the acidic conditions proceeded in good yield to provide 76 
(Scheme 29). The final and key step was settled. Treatment of the vinylpyrone 76 with SmI2 in the 
presence of iso-propanol promoted the reductive de-conjugation to give (+)-actinopyrone A (60).31 
In the presence of methanol, alternated with iso-propanol, the methyl ether 95 was obtained as 
byproduct from 93 by protonation without removal of methoxide. The generated 60 was 
accompanied with the 7,8-Z-isomer (60/7,8-Z-isomer = 88/12). The isomer were easily separated 
by silica gel column chromatography to isolate 60 in 70% yield. 
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Scheme 29. 
 
 
        The synthetic 60 was identical in all respects with the natural product, including 
spectroscopic characteristics (1H and 13C-NMR spectra, and mass spectra) and optical rotation 
[synthetic 60: [α]D25 +31.3 (c 0.43, CH2Cl2), natural product: [α]D26 +30.8 (c 0.42, CH2Cl2)]. Thus, 
the absolute structure of (+)-actinopyrone A (60) was determined to be (14R,15R)-configuration.  
     In conclusion, (+)-actinopyrone A (60) was synthesized from silyl dienolate 77 in 9 steps 
including the remote stereoinduction, Kocienski olefination, Horner–Wadsworth–Emmons 
olefination, and reductive de-conjugation with SmI2 and iso-propanol. A concise method has also 
been established by O-methylation to obtain the γ-pyrone. We also synthesized the enantiomer of 
60 showing the opposite opticalrotation [[α]D23 –31.7 (c 0.43, CH2Cl2)] by starting from the 
enantiomer of 77 derived from L-valine.  
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3. Total Synthesis of TMC-264, an Inhibitor of IL-4 Signal Transduction 
 
 
3.1. Introduction 
 
 
     Interleukin (IL)-4 is known to be a cytokine which plays a central role in the regulation of 
immune response. Binding of IL-4 to its receptor on B cells leads to the activation of the janus 
kinase (JAK)-signal transducer and activator transcription 6 (STAT6) pathway. In this pathway, the 
receptor associated JAK1 and 3 phosphorylates tyrosine residue of STAT6. Then STAT6 forms 
dimers, translocates to the nucleus, binds the specific elements in the promoters of target genes, and 
transcriptionally activates these genes. As a result, B cells raise expression of CD23 and class 
switching to IgE. Production of IgE causes the release of various chemical mediators such as 
histamine, leukotriene, prostaglandin and so on. Therefore, inhibitors of IL-4 signal transduction are 
expected to prevent allergic diseases.32 During the course of screening of microbial extracts for 
inhibitor of IL-4 signal transduction using an IL-4 driven luciferase assay system, a novel 
compound, TMC-264 (96), was discovered from the fermentation broth of a fungus Phoma sp. TC 
1674 (Figure 10).33 And the structure is determined to be 2-chloro-4,6-dihydro-1,7-dihydroxy-3,9-
dimethoxy-1-methyl-1H-dibenzo[b,d]pyran-4,6-dione.34 TMC-264 (96) is the first compound 
possessing 4,6-dione or possessing 1-hydroxy group on 1-methyl-dibenzo[b,d]-pyran. 
     Deacetylravidomycin (97) showed the same bioactivity. Known antiallergic agents, such as 
olopatadine hydrochloride (98), ketotifen (99) and sodium cromoglicate (100), elicited their 
antiallergic effects by mainly antagonizing histamine H1 receptors or worked by inhibiting release 
of chemical mediators. Thus TMC-264 (96) and deacetylravidomycin (97) represented a new class 
of antiallergic agents. 
     We hope the total synthesis of TMC-264 (96) would assist the elucidation of the novel 
bioactive system. 
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Figure 10. Antiallergic agents. 
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3.2. Retrosynthetic Analysis 
  
 
     Scheme 30 illustrates our retrosynthetic analysis of TMC-264 (96). Our strategy is based on 
the synthesis of racemic TMC-264 through oxidation which was followed by biaryl coupling 
reaction and acylation of 101 and 103. The highly substituted phenol 101 and benzoic acid 103 
were synthesized from commercially available 102 and 104, respectively. Thus, we examined the 
three significant steps including regioselective halogenation, selective protection of catechol 
segment, and biaryl coupling reaction to construct tricyclic compound as the priorities. 
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Scheme 30. Retrosynthetic analysis of TMC-264 (96). 
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3.3. Synthesis of Highly Substituted Phenol and Benzoic acid 
 
     The first matter of concern was regioselective halogenation. After deprotection of the 
trimethoxy compound 102 by BBr3 affording 105, halogenation of 105 was examined under 
several conditions (Scheme 31, Table 6). Finally, the best result was reallized bromination of 105 
by NBS in CCl4 at 0 °C generated the bromide 106 in high yield, accompanied with byproduct 
including 107 (Table 6, Entry 3). The structure of 106 was determined by NOE (Figure 11).  
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Scheme 31. 
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Figure 11. NOE of 106. 
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     After the protection of the diol 105 affording 108, several conditions were also examined to 
halogenate (Scheme 32). Under some conditions illustrated in Table 2, the desired compound was 
obtained in high regioselectivity (Entry 7 or 10). However, this route required extra 2 steps, which 
was protection and deprotection. Thus, we progressed the synthesis with using the bromide 106. 
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Scheme 32.  
 
Entry Substitution Condition Ratio 
 X R Reagent Solv. Additive Temp. 108 : 109 : 110 : Other
1 Cl H NCS CCl4 None rt 1 : 1 : 0.7 : 0.5 
2 Br H NBS MeCN None 0 ℃ 0 : 20 : 1 : 7 
3 Br H NBS CCl4 None 0 ℃ 1 : 20 : 2 : 1.7 
4 Br H NBS PhMe None 0 ℃ 1 : 13 : 0 : 2 
5 I H NIS CCl4 None rt 1 : 0.5 : 0 : 0 
6 Cl Ac NCS MeCN None 50 ℃ 0 : 12 : 1 : 1 
7 Br Ac NBS MeCN None 70 ℃ 0 : 1 : 0 : 0 
8 Cl TBS NCS MeCN None 80 ℃ 0 : 0.8 : 1 : 0 
9 Br TBS NBS MeCN None 50 ℃ 0 : 6 : 1 : 0.2 
10 Br TBS NBS CCl4 None 50 ℃ 0 : 13 : 1 : 0 
11 I TBS NIS MeCN None 60 ℃ 40 : 3 : 1 : 0 
12 I TBS NIS MeCN AIBN 60 ℃ 14 : 3.5 : 1 : 0 
 
Table 2. 
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  After chlorination of 106, protection of the catechol 111 with methoxymethyl ether afforded 
the three compounds including 112-114 under general conditions (Scheme 33).  
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Scheme 33. 
 
 
     On the other hand, tetrasubstituted benzoic acid 117 and 103 was synthesised from 
commercially available 115 and 104 in 2 steps, respectively (Scheme 34). Regioselective 
halogenation was followed by halogen-metalexchange to react with carbon dioxide to yield desired 
carboxylic acid. 
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Scheme 34. 
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     According to the synthetic route to protect the diol 105 in Scheme 32, it was observed that 
silyl and acyl group migrated in the two hydroxy (Figure 12).  
 
Me
OH
OR
OMe Me
OR
OH
OMe
119 : R = TBS or Ac 120 : R = TBS or Ac  
Figure 12. 
 
 
    Thus, 111 would be acylated with 119 to afford 121 and 122, migrated to each other, which 
were expected to react under the condition of biaryl coupling reaction when the benzoyl moiety was 
acylated at C-4a (Scheme 35). However, the reaction was resulted in the disappointment and 
multiple compounds were obtained. 
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Scheme 35. 
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     We concerned the methodology of the protection which was utilized to synthesis of 
kanamycin derivaties.35 After numerous examinations, selective protection of catechol was reallized 
that treatment of the catechol 111 with ZnCl2 and i-Pr2NEt in DMF, and subsequent MOMCl 
afforded 112 in high yield (Scheme 36, Table 3, Entry 11). We confirmed the structure of both 
mono methoxymethylated products, 112 and 113, by NOE (Figure 13). 
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Scheme 36. 
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Figure 13. NOE of 112 and 113 
 
 
 Entry Condition Ratio 
 Chloride Base Solv. Additive Temp. 112 : 113 : 114 : Other 
1 MOMCl i-Pr2NEt DMF Zn(OAc)2・2H2O –40 ℃ 3 : 1 : 1 : 0 
2 〃 〃 〃 〃 0 ℃ 3 : 1 : 0 : 0 
3 K2CO3〃 〃 〃 〃 0 : 0 : 1 : 0 
4 Et3N 〃 〃 〃 〃 2.5 : 1 : 0.5 : 0 
5 DMAP 〃 〃 〃 〃 1.7 : 1 : 0.3 : 0 
6 i-Pr2NEt Ni(OAc)2 4H2O〃 〃 ・ 〃 1 : 1 : 0.5 : 0.5 
7 Cu(OAc)2〃 〃 〃 〃 3 : 1 : 1 : 1 
8 CuCl2〃 〃 〃 〃 5 : 1 : 2 : 3 
9 CuBr2〃 〃 〃 〃 3 : 1 : 2 : 1 
10 Zn(OBz)2〃 〃 〃 〃 3 : 1 : 0.5 : 0 
11 ZnCl2〃 〃 〃 〃 6 : 1 : 0.2 : 0 
12 ZnBr2 3 : 1 : 1 : 0 〃 〃 〃 〃
 
Table 3. 
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3.4. Total Synthesis of TMC-264 
 
  
     Our attention was turned to intramoleculer coupling reaction. The Stille reaction and the 
Suzuki reaction were useful palladium-catalyzed carbon-carbon bond-forming reaction (Figure 14). 
The Heck reaction was also applied as a palladium-catalyzed coupling of aryl halides.36 
 
Me
O
OMOM
OMe
Y
Cl
OOMe
MeO X
124 : X or Y = H, Cl, Br, I, B(OR)2, SnR3  
Figure 14. 
 
 
     The desired organotin or organoboron compounds were not obtained, on the other hand, the 
precursor 126 was prepared from the benzoic acid 125 to examine the Heck reaction (Scheme 37).  
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Scheme 37. 
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     The oxidative addition to 126 was not underwent smoothly and starting material was 
recovered under the mild condition (Scheme 38). Several conditions were attempted with Pd(OAc)2 
or Pd(PPh3)2Cl2. Some base (Et3N, K2CO3, NaOAc, AgNO3) and additive (TBAC, PPh3) were 
added to generate desired compound. However, multiple compunds were afforded, including the 
hydrogenated compound 130 at C-10b, simultaneously deacylated when heated. Additionally, the 
iodinated compound at C-10b instead of the bromide compound 126 was also reached same result. 
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Scheme 38. 
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     Synthetic procedures for the preparation of biaryls by the classical Ullmann-type reaction had, 
in recent years, been supplanted by the use of zerovalent nickel to effect the reductive coupling of 
aryl halides under homogeneous conditions.37 We prepared the precursor 132 from the benzoic acid 
117 through the acid chloride 131 (Scheme 39). And fortunatelly, treatment of 132 with Ni(COD)2 
in DMF was underwent to generate the tricyclic compound 127 and hydrogenated 126. 
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Scheme 39. 
 
 
     This result suggested that oxidative addition at C-10a was faster than at C-10b. And the 
oxidative addition affording 134 was competed with affording 126 (Scheme 40). 
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Scheme 40. 
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    Thus we prepared the precursor 136, possessing chlorine at C-10a position, from 103 through 
acid chloride 135 (Scheme 41). We meaned to suppress the first oxidative addition at C-10a and 
second oxidative addition at C-10b would be occurred. Cyclization of 136 with Ni(COD)2 and 
EtAlCl2 in DMF gave the corresponding 127.  
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Scheme 41. 
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     Mechanism of the cyclization was illustrated in Scheme 42 by nickel-catalyzed coupling of 
aryl halide. The mechanism initiated with oxidative addition of aryl chloride and aryl bromide to 
zero-valent nickel afforded 138, followed by methathesis to diarylnickel(Ⅱ) species 139 
accompanied nickel(Ⅱ) halide, which would not be underwent any more. Thus, this reaction 
consumed stoichiometric amount of Ni(COD)2. And reductive elimination from diarylnickel(Ⅱ) 
species 139 gave cyclic 127 and regenerates zero-valent nickel. However, the formation of 
diarylnickel(Ⅱ) species via methathesis had not been demonstrated in detail and was still 
controversial. 38 
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     Final step is illustrated in Scheme 43. Selective deprotection was achieved by BCl3 according 
to carbonyl function and the phenol 141 was afforded. Oxidation of para-substituted phenol is 
generally slower and provides a more complex mixture of products. Ortho oxidized products and 
hydroperoxidated products would be obtained. Oxidation of the phenol 141 with oxygen activated 
by [bis-(salicylidene) ethylenediamine]cobalt (salcomine) generated racemic TMC-264 (96) in 60% 
yield.39   
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Scheme 43. 
 
 
     The synthetic TMC-264 (96) was identical in spectroscopic characteristics (1H and 13C-NMR 
spectra, MASS spectrum and IR spectrum) with the natural product. Thus, the structure of TMC-
264 (96) was confirmed. 
   In conclusion, highly substituted two segments were synthesized regioselectively. Especially, 
selective protection of catechol was achieved by methoxymethylation with MOMCl and ZnCl2. 
Biaryl coupling reaction was underwent by zero-valent nickel catalyzed cyclization. Subsequent 
oxidation generated TMC-264. 
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Summary 
 
 
     This dissertation was summarized as below. 
 
1. Total Synthesis of a Tetracyclic Antibiotic, (–)-Tetrodecamycin. 
 
1-1. Stereoselective Construction of trans-Decaline 
 
     Trans-decaline including the one cyclohexane ring of which was fully and diversely 
substituted was synthesized from D-(–)-mannitol through stereoselective Michael addition, aldol 
reaction, 1,4-reduction, SmI2-mediated pinacol cyclization. 
 
1-2. Construction of 7-Membered Ring 
 
     Construction of 7-memberd ring was achieved through the two critical steps, enol 
etherification and subsequent acylation. In addition, it was realized that the reaction order 
proceeded the successful cyclization. 
 
1-3. Total Synthesis of (–)-Tetrodecamycin 
 
     Tetracyclic core was established by regioselective hydrolysis, thio esterification, silane 
reduction and our newly developed deoxygenation, effected in one operation using CBr4 and PPh3. 
Subsequent steps including introduction of exo-methylene group gave (–)-tetrodecamycin, which 
was identical all respects with the natural product, and completed the first stereoselective total 
synthesis to confirm the absolute structure. 
 
 
2. Total Synthesis and Structural Determination of (+)-Actinopyrone A 
 
2-1. Synthesis of Significant Segments 
 
     The chiral C-14 and C-15 were constructed by Hosokawa's methodology using the chiral 
vinylketene, which was prepared from D-valine. And a concise method has also been established by 
O-methylation to obtain the γ-pyrone. 
 
2-2. Total Synthesis of (+)-Actinopyrone A 
 
     (+)-Actinopyrone A was obtained from silyl dienolate in 9 steps including the remote 
stereoinduction, Kocienski olefination, Horner–Wadsworth–Emmons olefination, and reductive de-
conjugation with SmI2 and iso-propanol afforded actinopyrone A, which was identical all respects 
with the natural product. The first stereoselective total snthesis was completed and confirmed (+)-
actinopyrone A to be (14R,15R)-configuration. We also synthesized the enantiomer of actinopyrone 
A showing the opposite opticalrotation by starting from L-valine. 
 
 
 
 
 
 
－42－ 
 
3. Total Synthesis of TMC-264, an inhibitor of IL-4 signal transduction 
 
3-1. Synthesis of Highly Substituted Phenol and Benzoic acid 
 
     Selective protection of catecohol was achieved by methoxymethylation with MOMCl and 
ZnCl2. And highly substituted two segments were synthesized regioselectively. 
 
3-2. Total Synthesis of TMC-264 
 
     Biaryl coupling reaction was underwent by zero-valent nickel catalyzed cyclization. 
Subsequent oxidation generated TMC-264, which was identical in spectroscopic characteristics (1H 
and 13C-NMR spectra, MASS spectrum and IR spectrum) with the natural product, and completed 
the first total synthesis to confirm the structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
－43－ 
Experimental Section 
 
General procedure 
 
1. Thin layer chromatography 
 
     All reactions were monitored by thin-layer chromatography using E. Merck silica gel 60F-
254 pre-coated plates (0.25 mm). 
 
2. Silica gel column chromatography 
 
     Chromatography was performed with indicated solvents using Fuji Siria Chemical silica gel 
BW-820MH and Kanto Chemical silica gel 60N. 
 
Instrument 
 
1. Optical rotation 
 
     Optical rotations were obtained on a JASCO DIP-360. 
 
2. Melting point 
 
     Melting points were obtained on a Yanako MP-S3 and are uncorrected. 
 
3. MASS spectrum 
 
     Mass spectra were acquired on a JEOL JMS-SX102A Mass spectrometer and JEOL JMS-
GCMATE Ⅱ. 
 
4. 1H-NMR spectrum 
 
     1H-NMR spectra were recorded on BRUKER AVANCE 600, JEOL AL 400 and JEOL AL 
300. Chemical shifts were shown in parts per million from internal tetramethylsilane on the δ  
scale and are referenced from the residual protium in the solvent (CHCl3 : δ 7.27). Data is reported 
as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br = broad), coupling constant in Hertz, assignment. 
 
5. 13C-NMR spectrum 
 
     13C-NMR spectra were recorded on BRUKER AVANCE 600, JEOL AL 400 and JEOL AL 
300. Chemical shifts were shown in parts per million from internal tetramethylsilane on the δ  
scale and are referenced from the carbon resonances of the solvent (CDCl3 : δ 77.0). 
 
6. Infrared spectrum 
 
     Infrared spectra were recorded on a JEOL JIR-WINSPEC 50 by KBr. 
 
7. X-ray crystallographic analysis 
 
     Diffractometer was Rigaku RAXIS-RAPID. 
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1. Total Synthesis of a Tetracyclic Antibiotic, (–)-Tetrodecamycin. 
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(1S,2S)-1,2-Bis((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethane-1,2-diol (11) 
 
 A mixture of D-(–)-mannitol (10) (57.9 g, 318 mmol) and campharsulfonic acid (7.39 g, 31.8 
mmol) in dimethylformamide (900 ml) was added dropwise over 12 hours acetone dimethylacetal 
(82.4 ml, 668 mmol) at 0 °C under nitrogen atmosphere. Sodium hydride (55%, 1.39 g, 31.8 mmol) 
was added, and the resulting mixture was concentrated under reduced pressure to afford crude 
diacetonide 11 (83.4 g, 318 mmol).  
 
Rf value: 0.32 (PhMe : EtOAc = 1 : 2). 
1H-NMR (600MHz, CDCl3): δ 1.35 (6H, s, IP), 1.41 (6H, s, IP), 2.64 (2H, br, OH-16), 3.74 (2H, m, 
H-16), 3.97 (2H, dd, J = 8.0, 5.0Hz, H-14), 4.12 (2H, dd, J = 8.0, 6.0Hz, H-14'), 4.18 (2H, ddd, J = 
6.0, 6.0, 5.0Hz, H-15). 
13C-NMR (150MHz, CDCl3): δ 25.17, 26.69, 66.71, 71.18, 76.24, 109.37. 
 
 
  
O
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(R)-2,2-Dimethyl-1,3-dioxolane-4-carbaldehyde (12) 
 
 To a vigorously stirred mixture of diacetonide 11 (83.4 g, 318 mmol) in dichloromethane (830 
ml) and saturated aqueous sodiumbicarbonate (42 ml) was added sodium pariodate (88.4 g, 413 
mmol) at 10 °C. The resulting mixture was stirred at room temperature for 6 hours, and then filtered. 
The filtrate was distilled to remove dichloromethane at atmospheric pressure, and then distilled to 
afford aldehyde 12 (37.1 g, 284 mmol) under reduced pressure.  
 
Rf value: 0.50 (hexane : EtOAc = 1 : 1). 
 
 
  
O O
13
CO2Me
O
O
14
HO
 
(Z)-Methyl 3-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate (13) 
(S)-5-(Hydroxymethyl)furan-2(5H)-one (14) 
 
 A solution of aldehyde 12 (37.1g, 284 mmol) in methanol (740 ml) was added 
triphenylphosphoranylidene aceticacid methylester (Ph3P=CHCO2Me, 143 g, 426 mmol) under 
nitrogen atmosphere, and left at room temperature for 14 hours. The mixture was concentrated 
under reduced pressure to give a residue, which was added a mixture of hexane-diethyl ether (2:1, 
500 ml). The resulting mixture was filtered, and the filtrate was concentrated under reduced 
pressure to afford crude α,β-unsaturated ester 13 until triphenylphosphine oxide and excess 
Ph3P=CHCO2Me were removed. The α,β-unsaturated ester 13 was dissolved in 0.1M hydrochloric 
acid methanol, which was prepared by acetyl chloride (37.1 g, 284 mmol) and methanol (300 ml), 
and left at room temperature for 20 minutes. The solution was concentrated under reduced pressure 
to afford crude α,β-unsaturated lactone 14 (24.6 g, 215 mmol). 
－45－ 
Rf value of 13: 0.43 (hexane : EtOAc = 3 : 1). 
1H-NMR (400MHz, Acetone-d6): δ 1.40 (3H, s, IP), 1.46 (3H, s, IP), 3.62 (1H, dd, J = 7.5, 6.0Hz, 
H-14), 3.73 (3H, s, CO2Me), 4.39 (1H, dd, J = 7.5, 6.0Hz, H-14'), 5.50 (1H, dddd, J = 6.0, 6.0, 6.0, 
1.5Hz, H-15), 5.86 (1H, dd, J = 11.0, 1.5Hz, H-7), 6.38 (1H, dd, J = 11.0, 6.0Hz, H-16). 
 
Rf value of 14: 0.36 (EtOAc only). 
1H-NMR (600MHz, Acetone-d6): δ 2.46 (1H, dd, J = 12.0, 3.5Hz, H-14), 2.62 (1H, dd, J = 12.0, 
2.0Hz, H-14'), 3.91 (1H, m, H-15), 4.93 (1H, d, J = 5.0Hz, H-7), 6.40 (1H, dd, J = 5.0, 0.5Hz, H-
16). 
13C-NMR (150MHz, CDCl3): δ 59.79, 83.68, 120.44, 154.04, 173.12. 
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(S)-5-((Triphenylmethyloxy)methyl)furan-2(5H)-one (9) 
 
 To a stirred mixture of α,β-unsaturated lactone 14 (24.6 g, 215 mmol) and triphenylmethyl 
chloride (71.7 g, 257 mmol) in N,N-dimethylformamide (500 ml) at room temperature was added 
ammonium nitrate (68.2 g, 852 mmol) under nitrogen atmosphere. The resulting mixture was stirred 
at room temperature for 15 hours, and poured into ice water to give a gum. The residue was purified 
on silica gel column chromatography (BW820-MH 1200 g, PhMe : EtOAc = 30 : 1) to afford 
trityloxy 9 (70.6 g, 198 mmol, 32% in 5 steps).  
 
Rf value: 0.28 (hexane : EtOAc = 3 : 1). 
[α]D26 –95.3° (c 1.87, CHCl3). 
HRFAB-MS (m/z): 356.1382 [M+H]+; calcd for C24H20O3: 356.1413. 
1H-NMR (600MHz, CDCl3): δ 3.36 (1H, dd, J = 9.5, 4.5Hz, H-14), 3.40 (1H, dd, J = 9.5, 4.5Hz, H-
14'), 5.05 (1H, dddd, J = 4.5, 4.5, 2.0, 1.0Hz, H-15), 6.15 (1H, dd, J = 5.5, 2.0Hz, H-7), 7.38 (1H, 
dd, J = 5.5, 1.0Hz, H-16). 
13C-NMR (150MHz, CDCl3): δ 63.36, 82.10, 86.92, 122.35, 127.22, 127.34, 127.76, 127.91, 128.03, 
128.13, 128.25, 128.32, 128.47, 128.65, 143.20, 154.18, 172.84. 
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(4S,5S)-Dihydro-4-methyl-5-((triphenylmethyloxy)methyl)furan-2(3H)-one (15) 
 
 A mixture of copper(І)bromidedimethylsulfidecomplex (3.05 g, 14.6 mmol) and hexamethyl-
phsphoramide (26.0 ml, 149 mmol) in tetrahydrofuran (250 ml) was cooled to –78 °C under 
nitrogen atmosphere. The mixtue was added 3.0M methylmagnesium bromide (61.0 ml, 183 mmol), 
trimethylsilylchloride (26.0 ml, 149 mmol) and a solution of trityloxy 9 (25.0 g, 70.1 mmol) in 
tetrahydrofuran (150 ml), and the temperature was spontaneously increased slowoly to –50 °C 1 
hour. Saturated aqueous ammonium chloride was added, and the resulting mixture was concentrated. 
Ethyl acetate (300 ml) was added and the layers were separated. The aqueous solution was extracted 
twice with ethyl acetate (300 ml×2), and the combined organic extracts were concentrated. The 
residue which was purified on silica gel column chromatography (BW820-MH 750 g, hexane : 
EtOAc = 3 : 1) to afford monomethyl 15 (23.0 g, 61.8 mmol, 88%).  
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Rf value: 0.37 (hexane : EtOAc = 3 : 1). 
[α]D23 +32.3° (c 0.98, CHCl3). 
HRFAB-MS (m/z): 467.2592 [M+H]+; calcd for C32H35O3: 467.2588. 
1H-NMR (600MHz, CDCl3): δ 0.74 (3H, d, J = 6.5Hz, Me-18), 1.19 (3H, s, Me-17), 1.48-1.56 (1H, 
m), 1.60-1.74 (3H, m), 1.97-2.19 (4H, m), 2.66 (1H, dq, J = 10.0, 6.5Hz, H-16), 3.17 (1H, dd, J = 
10.5, 4.0Hz, H-14), 3.50 (1H, dd, J = 10.5, 3.0Hz, H-14'), 4.08 (1H, ddd, J = 10.0, 4.0, 3.0Hz, H-
15), 5.65 (1H, m, H-9), 7.21-7.35 (9H, m), 7.44-7.51 (6H, m). 
13C-NMR (150MHz, CDCl3): δ 10.36, 15.15, 22.17, 22.99, 25.41, 25.87, 38.03, 52.41, 62.55, 82.57, 
86.73, 124.46, 127.12, 127.88, 128.64, 135.77, 143.60, 180.14. 
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(3R,4S,5S)-Dihydro-3,4-dimethyl-5-((triphenylmethyloxy)methyl)furan-2(3H)-one 
(16) 
 
 A stirred solution of diisopropylamine (18 ml, 126 mmol) in tetrahydrofuran (122 ml) was added 
2.66M solution of n-butyllithium in hexane (41 ml, 108 mmol) at 0 °C under nitrogen atmosphere, 
and cooled to –78 °C. A solution of monomethyl 15 (33.6 g, 90.1 mmol) in tetrahydrofuran (330 
ml) was added, and followed by methyl iodide (34 ml, 541 mmol). Acetic acid (13 ml, 234 mmol) 
was added and the resulting mixture was concentrated. Water (150 ml) and ethyl acetate (500 ml) 
were added, and the layers were separated. The aqueous solution was extracted twice with ethyl 
acetate (500 ml×2), and the combined organic extracts were concentrated to afford dimethyl 16 
(32.7 g, 84.7 mmol).  
 
Rf value: 0.40 (hexane : EtOAc = 4 : 1). 
[α]D25 +31.6° (c 0.93, CHCl3). 
HRFAB-MS (m/z): 467.2592 [M+H]+; calcd for C32H35O3: 467.2588. 
1H-NMR (600MHz, CDCl3): δ 0.74 (3H, d, J = 6.5Hz, Me-18), 1.19 (3H, s, Me-17), 1.48-1.56 (1H, 
m), 1.60-1.74 (3H, m), 1.97-2.19 (4H, m), 2.66 (1H, dq, J = 10.0, 6.5Hz, H-16), 3.17 (1H, dd, J = 
10.5, 4.0Hz, H-14), 3.50 (1H, dd, J = 10.5, 3.0Hz, H-14'), 4.08 (1H, ddd, J = 10.0, 4.0, 3.0Hz, H-
15), 5.65 (1H, m, H-9), 7.21-7.35 (9H, m), 7.44-7.51 (6H, m). 
13C-NMR (150MHz, CDCl3): δ 10.36, 15.15, 22.17, 22.99, 25.41, 25.87, 38.03, 52.41, 62.55, 82.57, 
86.73, 124.46, 127.12, 127.88, 128.64, 135.77, 143.60, 180.14. 
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(3S,4S,5S)-Dihydro-3-(1-hydroxycyclohexyl)-3,4-dimethyl-5-
((triphenylmethyloxy)methyl) furan-2(3H)-one (17) 
 
 A stirred solution of diisopropylamine (57 ml, 406 mmol) in tetrahydrofuran (350 ml) was added 
2.66M solution of n-butyllithium in hexane (145 ml, 386 mmol) at 0 °C under nitrogen atmosphere, 
and cooled to –78 °C. A solution of dimethyl 16 (32.7 g, 84.7 mmol) in tetrahydrofuran (300 ml) 
was added, and followed by cyclohexanone (30 ml, 290 mmol). Acetic acid (45 ml, 792 mmol) was 
added and the mixture was concentrated. Water (150 ml) and ethyl acetate (500 ml) were added, and 
the layers were separated. The aqueous solution was extracted twice with ethyl acetate (500 ml×2), 
and the combined organic extracts were concentrated under reduced pressure to afforded aldol 
adduct compound 17 (38.8 g, 80.1 mmol).  
 
Rf value: 0.24 (PhMe : EtOAc = 20 : 1). 
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(3S,4R,5S)-3-Cyclohexenyl-dihydro-3,4-dimethyl-5-
((triphenylmethyloxy)methyl)furan-2(3H)-one (8) 
 
 A stirred solution of aldol adduct compound 17 (38.8 g, 80.1 mmol) in pyridine (600 ml) was 
added thionyl chloride (42 ml, 580 mmol) at 0 °C and stirred for 30 minutes under nitrogen 
atmosphere. The mixture was puored into ice water, and then ethyl acetate (600 ml) was added. The 
layers were separated, and the aqueous solution was extracted twice with ethyl acetate (600 ml×2). 
The combined organic extracts were concentrated, and the residue was purified on silica gel column 
chromatography (BW820-MH 1600 g, hexane : EtOAc = 6 : 1) to afford cyclohexene 8 (33.1 g, 
71.0 mmol, 79% in 3 steps).  
 
Rf value: 0.45 (PhMe : EtOAc = 20 : 1). 
needles recrystallized from iso-propanol; m.p. 153.5 °C. 
[α]D28 +21.8° (c 0.95, CHCl3). 
HRFAB-MS (m/z): 467.2592 [M+H]+; calcd for C32H35O3: 467.2588. 
1H-NMR (600MHz, CDCl3): δ 0.74 (3H, d, J = 6.5Hz, Me-18), 1.19 (3H, s, Me-17), 1.48-1.56 (1H, 
m), 1.60-1.74 (3H, m), 1.97-2.19 (4H, m), 2.66 (1H, dq, J = 10.0, 6.5Hz, H-16), 3.17 (1H, dd, J = 
10.5, 4.0Hz, H-14), 3.50 (1H, dd, J = 10.5, 3.0Hz, H-14'), 4.08 (1H, ddd, J = 10.0, 4.0, 3.0Hz, H-
15), 5.65 (1H, m, H-9), 7.21-7.35 (9H, m), 7.44-7.51 (6H, m). 
13C-NMR (150MHz, CDCl3): δ 10.36, 15.15, 22.17, 22.99, 25.41, 25.87, 38.03, 52.41, 62.55, 82.57, 
86.73, 124.46, 127.12, 127.88, 128.64, 135.77, 143.60, 180.14. 
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(2R,3S,4S)-2-Cyclohexenyl-2,3-dimethyl-5-(triphenylmethyloxy)pentane-1,4-diol 
(23) 
 
 A mixture of lithium bromide (15.6 g, 180 mmol) in tetrahydrofuran (200 ml) was added sodium 
borohydride (6.5 g, 171 mmol) at 0 °C under nitrogen atmosphere, and the mixture was stirred at 
65 °C for 12 hours. A solution of cyclohexene 8 (20.0 g, 42.9 mmol) was added at room 
temperature, and the resulting mixture was stirred at 65 °C for 14 hours. Lithium borohydride (9.3 g, 
425 mmol) was added and stirring continued for 3 hours. Acetic acid (137 ml, 792 mmol) and 
methanol (200 ml) was added then concentrated under reduced pressure. Water (200 ml) and ethyl 
acetate (600 ml) was added and the layers were separated. The aqueous solution was extracted twice 
with ethyl acetate (600 ml×2). The combined organic extracts were concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 600 g, hexane : 
EtOAc = 3 : 1) to afford diol 23 (20.0 g, 42.5 mmol). 
 
Rf value: 0.30 (hexane : EtOAc = 3 : 1). 
1H-NMR (600MHz, CDCl3): δ 0.44 (3H, d, J = 6.5Hz, Me-18), 0.86 (3H, s, Me-17), 1.44-1.62 (4H, 
m), 1.81-1.89 (1H, m), 1.89 (1H, dd, J = 8.5, 6.5Hz, H-16), 1.99-2.09 (3H, m), 3.06 (1H, dd, J = 8.5, 
8.5Hz, H-14'), 3.24-3.43 (1H, br, OH), 3.38 (1H, dd, J = 8.5, 2.5Hz, H-14'), 3.49 (1H, d, J = 10.5Hz, 
H-6), 3.60 (1H, d, J = 10.5Hz, H-6'), 3.63 (1H, ddd, J = 8.5, 8.5, 2.5Hz, h-15), 5.49 (1H, m, H-9), 
7.24-7.29 (3H, m), 7.30-7.36 (3H, m), 7.42-7.48 (3H, m).  
13C-NMR (150MHz, CDCl3): δ 11.48, 15.24, 22.38, 23.38, 24.91, 25.61, 38.84, 47.53, 66.96, 70.22, 
71.38, 87.14, 121.88, 127.21, 127.92, 128.54, 141.84, 143.69, 143.84. 
 
 
 
(2S,3S,4R)-4-((Benzyloxy)methyl)-4-cyclohexenyl-3-methyl-1-(triphenylmethyloxy)pentan-2-ol  
 
 A mixture of diol 23 (20.0 g, 42.5 mmol), 18-crown-6-ether (5.6 g, 21.3 mmol) and potassium 
carbonate (17.6 g, 127 mmol) in acetonitrile (400 ml) was added benzyl bromide (7.6 ml, 63.7 
mmol) under nitrogen atmosphere, and stirred at 50 °C for 8 hours. Acetic acid (137 ml, 792 mmol) 
was added then concentrated under reduced pressure. Water (200 ml) and ethyl acetate (600 ml) was 
added and the layers were separated. The aqueous solution was extracted twice with ethyl acetate 
(600 ml×2), and the combined organic extracts were concentrated to afford crude benzyl compound 
(20.1 g, 37.7 mmol).  
 
Rf value: 0.41 (hexane : EtOAc = 8 : 1). 
1H-NMR (600MHz, CDCl3): δ 0.47 (3H, d, J = 6.5Hz, Me-18), 0.94 (3H, s, Me-17), 1.47-1.64 (4H, 
m), 1.83-1.93 (1H, m), 1.97-2.07 (4H, m), 3.01 (1H, dd, J = 8.5, 5.5Hz, H-14), 3.31 (1H, dd, J = 8.5, 
2.5Hz, H-14'), 3.46 (1H, d, J = 8.5Hz, H-6), 3.46 (1H, d, J = 3.0Hz, OH-15), 3.55 (1H, d, J = 8.5Hz, 
H-6'), 3.60 (1H, ddd, J = 6.5, 5.5, 2.5Hz, H-15), 4.44 (1H, d, J = 11.5Hz, OCH2Ph), 4.50 (1H, d, J = 
11.5Hz, OCH2Ph), 5.45 (1H, m, H-9), 7.21-7.39 (14H, m), 7.43-7.49 (6H, m).  
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((2S,3S,4R)-4-((Benzyloxy)methyl)-4-cyclohexenyl-3-methyl-1-
(triphenylmethyloxy)pentan-2-yloxy)(tert-butyl)dimethylsilane (24) 
 
 A solution of crude benzyl compound (20.0 g, 42.5 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-
ene (5.6 ml, 21.3 mmol) in acetonitrile (400 ml) was added t-butyldimethylsilyl chloride (17.6 g, 
127 mmol) under nitrogen atmosphere, and left at 65 °C for 20 hours. The resulting solution was 
concentrated under reduced pressure. The residue was purified on silica gel column 
chromatography (BW820-MH 600 g, hexane : EtOAc = 15 : 1) to afford silyl compound 24 (24.1 
g, 35.8 mmol, 85% in 3 steps).  
 
Rf value: 0.38 (hexane : EtOAc = 20 : 1). 
[α]D23 –3.8° (c 1.16, MeOH). 
HRFAB-MS (m/z): 697.4030 [M+Na]+; calcd for C45H58O3SiNa: 697.4053. 
1H-NMR (600MHz, CDCl3): δ 0.10 (3H, s, SiMe), 0.18 (3H, s, SiMe), 0.58 (3H, d, J = 7.0Hz, Me-
18), 0.76 (3H, s, Me-17), 0.93 (9H, s, SitBu), 1.44-1.56 (4H, m), 1.73-1.87 (3H, m), 1.92-2.06 (2H, 
m), 2.96 (1H, dd, J = 10.0, 2.0Hz, H-14), 3.10 (1H, dd, J = 10.0, 8.0Hz, H-14'), 3.24 (1H, d, J = 
9.0Hz, H-6), 3.27 (1H, d, J = 9.0Hz, H-6'), 4.07 (1H, ddd, J = 8.0, 2.0, 2.0Hz, H-15), 4.36 (2H, s, 
OCH2Ph), 5.28 (1H, m, H-9), 7.19-7.32 (14H, m), 7.44-7.50 (6H, m).  
13C-NMR (150MHz, CDCl3): δ –4.44, –3.96, 9.16, 18.06, 18.99, 22.31, 23.32, 24.70, 25.58, 25.96, 
44.38, 45.00, 67.46, 73.10, 73.25, 75.97, 86.43, 121.81, 126.75, 127.28, 127.45, 127.58, 128.17, 
128.91, 138.71, 140.48, 144.38. 
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2,3-Dideoxy-4-O-((1,1-dimethylethylsilyl)-2,3-dimethyl-2-(6-oxo-1-cyclohexen-1-
yl)-1-O-(phenylmethyl)-5-O-(triphenylmethyl)-(2R)-D-erythro-pentitol (27) 
 
 
 A solution of silyl compound 24 (1.10 g, 1.63 mmol) in 97% aqueous dioxane (33 ml) was added 
selenium dioxide (608 mg, 5.48 mmol), and left at 90 °C for 17 hours. The mixture was 
concentrated under reduced pressure. The residue was purified on silica gel column 
chromatography (BW820-MH 55 g, hexane : EtOAc = 5 : 1) to afford α,β-unsaturated ketone 27 
(24.1 g, 35.8 mmol, 86%).  
 
Rf value: 0.33 (hexane : Et2O = 5 : 1). 
[α]D27 –4.0° (c 1.18, MeOH). 
HRFAB-MS (m/z): 711.3839 [M+Na]+; calcd for C45H56O4SiNa: 711.3846. 
1H-NMR (600MHz, CDCl3): δ 0.19 (3H, s, SiMe), 0.20 (3H, s, SiMe), 0.50 (3H, d, 7.0Hz, Me-18), 
0.74 (3H, s, Me-17), 0.95 (9H, s, SitBu), 1.81-1.92 (2H, m), 2.24-2.39 (4H, m), 2.52 (1H, dq, J = 
7.0, 2.0Hz, H-16), 2.94 (1H, dd, J = 9.5, 1.5Hz, H-14), 3.13 (1H, dd, J = 9.5, 7.5Hz, H-14'), 3.44 
(1H, d, J = 8.0Hz, H-6), 3.92 (1H, d, J = 8.0Hz, H-6'), 4.01 (1H, ddd, J = 7.5, 2.0, 1.5Hz, H-15), 
4.33 (2H, s, OCH2Ph), 6.43 (1H, dd, J = 4.0, 4.0Hz, H-9), 7.18-7.32 (14H, m), 7.44-7.51 (6H, m).  
13C-NMR (150MHz, CDCl3): δ –4.45, –4.11, 9.62, 18.06, 19.13, 22.53, 22.65, 25.98, 26.56, 40.20, 
42.40, 45.04, 67.57, 73.06, 73.19, 76.02, 86.44, 126.74, 127.22, 127.32, 127.59, 128.13, 128.90, 
138.84, 142.37, 144.35, 145.73, 199.37. 
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2,3-Dideoxy-4-O-((1,1-dimethylethylsilyl)-2,3-dimethyl-2-((1S)-2-oxocyclohexyl)-1-O-
(phenylmethyl)-5-O-(tripheny-lmethyl)-(2R)-D-erythro-pentitol (28)  
2,3-Dideoxy-4-O-((1,1-dimethyl-ethylsilyl)-2,3-dimethyl-2-((1R)-2-oxocyclohexyl)-1-O-(phenyl-
methyl)-5-O-(triphenylmethyl)-(2R)-D-erythro-pentitol (29) 
 
 A solution of α,β-unsaturated ketone 27 (166 mg, 242 μmol) in dichloromethane (0.9 ml) and 
methanol (4.1 ml) was added nickel chloride hexahydrate (33.2 mg, 140 μmol) under nitrogen 
atmosphere, and cooled to 0 °C. Sodium borohydride (46.8 mg, 1.24 μmol) was added, then stirred 
for 10 minutes. The mixture was concentrated under reduced pressure, and the resulting residue was 
purified on silica gel column chromatography (BW820-MH 10 g, PhMe : cyclohexane = 5 : 1) to 
afford desired stereochemical compound 28 (128 mg, 185 μmol, 82%) and undesired 
stereochemical compound 29 (16.7 mg, 24.2 μmol, 10%).  
 
Rf value of 28: 0.51 (PhMe : cyclohexane = 3 : 1). 
needles recrystallized from methanol; m.p. 114.6 ° C. 
[α]D23 +4.0° (c 0.82, CHCl3), [α]D25 +7.9° (c 0.16, MeOH). 
HRFAB-MS (m/z): 713.4010 [M+Na]+; calcd for C45H58O4SiNa: 713.4004. 
1H-NMR (600MHz, CDCl3): δ 0.10 (3H, s, SiMe), 0.16 (3H, s, SiMe), 0.62 (3H, s, Me-17), 0.70 
(3H, d, J = 8.0Hz, Me-18), 0.93 (9H, s, SitBu), 1.44-1.56 (2H, m), 1.59-1.68 (1H, m), 1.79-1.86 (1H, 
m), 1.92-1.98 (1H, m), 1.99-2.05 (1H, m), 2.20 (1H, dq, J = 3.0, 8.0Hz, H-16), 2.25-2.33 (2H, m), 
2.51 (1H, dd, J = 12.0, 4.5Hz, H-8), 3.11 (1H, dd, J = 10.0, 8.0Hz, H-14), 3.16 (1H, dd, J = 10.0, 
2.0Hz, H-14'), 3.20 (2H, s, H-6), 4.08 (1H, ddd, J = 8.0, 3.0, 2.0Hz, H-15), 4.09 (1H, d, J = 12.0Hz, 
OCH2Ph), 4.17 (1H, d, J = 12.0Hz, OCH2Ph), 7.15-7.31 (14H, m), 7.43-7.50 (6H, m).  
13C-NMR (150MHz, CDCl3): δ –4.58, –4.17, 8.92, 17.97, 18.09, 25.82, 26.01, 26.35, 28.60, 30.09, 
40.67, 42.47, 44.39, 55.24, 67.12, 72.83, 73.21, 86.42, 126.71, 127.32, 127.55, 127.61, 127.90, 
128.13, 128.95, 138.43, 144.47, 213.22.  
 
Rf value of 29: 0.46 (PhMe : cyclohexane = 3 : 1). 
needles recrystallized from methanol; m.p. 93.6 ° C. 
[α]D25 +24° (c 1.34, CHCl3), [α]D26 +29° (c 0.41, MeOH). 
HRFAB-MS (m/z): 713.4010 [M+Na]+; calcd for C45H58O4SiNa: 713.4004. 
1H-NMR (600MHz, CDCl3): δ 0.16 (3H, s, SiMe), 0.19 (3H, s, SiMe), 0.62 (3H, s, Me-17), 0.66 
(3H, d, J = 7.0Hz, Me-18), 0.94 (9H, s, SitBu), 1.40-1.57 (2H, m), 1.58-1.67 (1H, m), 1.79-1.87 (1H, 
m), 1.95-2.06 (3H, m), 2.18-2.29 (2H, m), 2.52 (1H, dd, J = 12.0, 4.5Hz, H-8), 3.06 (1H, dd, J = 
10.0, 1.5Hz, H-14), 3.17 (1H, dd, J = 10.0, 7.5Hz, H-14'), 3.28 (1H, d, J = 9.5Hz, H-6), 3.51 (1H, d, 
J = 9.5Hz, H-6'), 4.08 (1H, d, J = 11.0Hz, OCH2Ph), 4.12 (1H, d, J = 11.0Hz, OCH2Ph), 4.25 (1H, 
ddd, J = 7.5, 2.0, 1.5Hz, H-15), 7.16-7.29 (14H, m), 7.42-7.49 (6H, m).  
13C-NMR (150MHz, CDCl3): δ –4.55, –3.90, 9.10, 17.95, 18.09, 25.99, 26.12, 28.69, 30.02, 40.95, 
44.01, 44.18, 55.19, 67.26, 72.71, 72.86, 73.30, 86.40, 126.70, 127.11, 127.36, 127.51, 128.07, 
129.01, 138.69, 144.37, 213.02.  
 
 
－51－ 
Epimerization of 29 to afford 28 
 
 A solution of undesired stereochemical compound 29 (5.33 g, 7.72 mmol) in methanol (110 ml) 
was added potassium hydroxide (650 mg, 11.7 mmol), and left at 60 °C for 2 hours. The mixture 
was cooled to room temperature, causing the product to crystallize. The mixture was filtered, and 
the crystals were washed twice with methanol (50 ml×2) and dried to afford desired stereochemical 
compound 28 (1.15 g, 1.67 mmol). The filtrate was concentrated under reduced pressure. The 
resulting residue was purified on silica gel column chromatography (BW820-MH 25 g, PhMe : 
cyclohexane = 5 : 1) to afford desired stereochemical compound 28 (2.05 g, 2.97 mmol, combined 
yield 82%).  
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2,3-Dideoxy-4-O-((1,1-dimethylethylsilyl)-2,3-dimethyl-2-((1S)-2-
oxocyclohexyl)-1-O-(phenylmethyl)-(2R)-D-erythro-pentitol (30) 
 
 A solution of desired stereochemical compound 28 (1.15 g, 1.67 mmol) in dichloromethane (23 
ml) was added 0.92M solution of diethyl aluminium chloride in hexane (7.3 ml, 6.72 mmol) at 0 °C 
under nitrogen atmosphere and stirred for 2 hours. Triethylamine (3.7 ml, 26.7 mmol) and water 
(600 μl, 33.3 mmol) was added, and the resulting mixture was filtered and washed twice with 
dichloromethane (23 ml×2). The filtrate was concentrated under reduced pressure to afford crude 
primary alcohol 30 (747 mg, 1.67 mmol).  
 
Rf value: 0.19 (hexane : EtOAc = 9 : 1). 
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3,4-Dideoxy-2-O-((1,1-dimethylethylsilyl)-2,3-dimethyl-4-((1S)-2-o
5-O-(phenylmethyl)-(4R)-L-erythro-pentose (7) 
xocyclohexyl)-
 
 A mixture of crude primary alcohol 30 (747 mg, 1.67 mmol) and neutral aluminu (1.07 g) in 
dichloromethane (15 ml) was added pyridinium chlorochromate (634 mg, 2.94 mmol) under 
nitrogen atmosphere, and stirred at room temperature for 6 hours. The mixture was filtered through 
celite and washed twice with dichloromethane (15 ml×2). The filtrate was concentrated under 
reduced pressure to afford crude keto-aldehyde 7 (747 mg, 1.67 mmol).  
 
Rf value: 0.42 (PhMe only). 
[α]D26 +21° (c 1.29, MeOH). 
HRFAB-MS (m/z): 445.2779 [M-H]+; calcd for C26H41O4Si: 445.2774. 
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1H-NMR (600MHz, CDCl3): δ -0.01 (3H, s, SiMe), 0.00 (3H, s, SiMe), 0.87 (9H, s, SitBu), 0.97 (3H, 
s, Me-17), 1.05 (3H, d, J = 7.5Hz, Me-18), 1.45-1.55 (1H, m), 1.56-1.71 (2H, m), 1.80-1.88 
(1H, m), 1.93-2.00 (1H, m), 2.02-2.10 (1H, m), 2.26-2.33 (1H, m), 2.33-2.40 (1H, m), 2.58 (1H, dq, 
J = 3.5, 7.5Hz, H-16), 2.82 (1H, dd, J = 12.5, 5.0Hz, H-8), 3.30 (2H, s, H-6), 3.95 (1H, dd, J = 3.5, 
3.0Hz, H-15), 4.26 (1H, d, J = 12.0Hz, OCH2Ph), 4.40 (1H, d, J = 12.0Hz, OCH2Ph), 7.24-7.30 (3H, 
m), 7.31-7.37 (2H, m), 9.43 (1H, d, J = 3.0Hz, H-14).  
13C-NMR (150MHz, CDCl3): δ –4.99, –4.71, 10.77, 17.77, 18.12, 25.75, 26.14, 28.63, 29.89, 41.10, 
41.23, 44.31, 53.86, 71.98, 72.55, 79.10, 127.63, 127.92, 128.28, 137.94, 200.11, 213.09. 
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2-(((1,1-Dimethylethyl)dimethylsilyl)oxy)octahydro-3,4-dimethyl-4-
((phenylmethoxy)methyl)-(1R,2S,3S,4R,4aS,8aS)-1,8a(1H)-naphthalenediol (31) 
 
 Keto-aldehyde 7 (570 mg, 1.28 mmol) and t-butanol (520 μl, 5.10 mmol) were dissolved in 
tetrahydrofuran (40 ml) under argon atmosphere at room temperature, and added 0.1M solution of 
samarium iodide in tetrahydrofuran (38.3 ml, 3.83 mmol) at –78 °C. The mixture was warmed to 
0 °C, and added saturated aqueous sodiumbicarbonate and 20% aqueous sodium thiosulfate (6 ml). 
The mixture was filtered, and washed twice with ethyl acetate (6 ml×2). The filtrate was 
concentrated under reduced pressure. The resulting residue was purified on silica gel column 
chromatography (BW820-MH 50 g, PhMe only) to afford diol 31 (462 mg, 1.03 mmol, 62% in 3 
steps).  
 
Rf value: 0.40 (PhMe only). 
[α]D25 +30° (c 1.07, MeOH). 
HRFAB-MS (m/z): 471.2913 [M+H]+; calcd for C26H44O4Si: 471.2907. 
1H-NMR (600MHz, CDCl3): δ 0.11 (3H, s, SiMe), 0.12 (3H, s, SiMe), 0.91 (3H, d, J = 7.0 Hz, Me-
18), 0.93 (9H, s, SitBu), 1.18 (3H, s, Me-17), 1.12-1.15 (2H, m), 1.31 (1H, m), 1.41 (1H, dd, J = 
12.0, 2.5 Hz, H-8), 1.51 (1H, m), 1.58 (1H, dddd, J = 12.5, 12.5, 12.5, 3.5 Hz), 1.64 (1H, ddddd, J = 
13.5, 13.5, 13.5, 4.0, 4.0 Hz), 1.75 (1H, m), 1.91-1.98 (2H, m), 1.95 (1H, dq, J = 7.0, 4.5 Hz, H-16), 
2.31 (1H, s), 3.16 (1H, d, J = 8.5 Hz, H-6), 3.20 (1H, d, J = 8.5 Hz, H-6'), 3.31 (1H, d, J = 9.5 Hz, 
H-14), 4.07 (1H, dd, J = 9.5, 4.5 Hz, H-15), 4.44 (1H, d, J = 11.5 Hz, OCH2Ph), 4.47 (1H, d, J = 
11.5 Hz, OCH2Ph), 7.24-7.37 (5H, m).  
13C-NMR (150MHz, CDCl3): δ –4.82, –4.23, 7.84, 18.09, 20.27, 20.91, 21.45, 25.86, 26.52, 37.46, 
40.50, 41.66, 43.08, 71.84, 73.13, 73.56, 74.98, 77.71, 127.21, 127.28, 128.05, 128.22, 138.90. 
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((3aR,4S,5S,6R,6aS,10aS)-6-((Benzyloxy)methyl)-octahydro-2,2,5,6-tetramethyl-
3aH-naphtho[1-d][1,3]dioxol-4-yloxy)(tert-butyl)dimethylsilane (33) 
 
 A mixture of diol 31 (142 mg, 327 μmol) and 2-methoxypropene (700 μl, 7.31 mmol) in 1,2-
dichloromethane (2.8 ml) was added pyridinium-p-toluenesulfonic acid (16 mg, 63.5 μmol) under 
nitrogen atmosphere, and left at room temperature for 8 hours. Triethylamine (885 μl, 6.35 mmol) 
was added and concentrated under reduced pressure. The residue was purified on silica gel column 
chromatography (BW820-MH 7 g, hexane : iPr2O  = 20 : 1) to afford acetonide 33 (115 mg, 234 
μmol, 74%).  
 
Rf value: 0.39 (hexane : iPr2O = 20 : 1). 
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(3aR,4S,5S,6R,6aS,10aS)-6-((Benzyloxy)methyl)-octahydro-2,2,5,6-tetramethyl-
3aH-naphtho[1-d][1,3]dioxol-4-ol (34) 
 
 Acetonide 33 (109 mg, 224 μmol) was dissolved in tetrahydrofuran (2.0 ml), and added 1.0M 
solution of tetra-n-butylammonium fluoride in tetrahydrofuran (670 μl, 670 μmol) under nitrogen 
atmosphere. The solution was left at 50 °C for 15 hours, and concentrated under reduced pressure. 
The residue was purified on silica gel column chromatography (BW820-MH 5 g, hexane : EtOAc = 
5 : 1) to afford secondary alcohol 34 (80.4 mg, 215 μmol, 96%).  
 
Rf value: 0.21 (hexane : EtOAc = 6 : 1). 
needles recrystallized from ethyl acetate; m.p. 134.6 ° C. 
[α]D28 +26° (c 1.57, MeOH).  
HRFAB-MS (m/z): 375.2532 [M+H]+; calcd for C23H34O4Si: 375.2535. 
1H-NMR (600MHz, CDCl3): δ 0.86 (3H, s, Me-17), 1.10 (3H, d, J = 6.5 Hz, Me-18), 1.21 (1H, 
ddddd, J = 12.5, 12.5, 12.5, 3.0, 3.0 Hz), 1.42 (1H, m), 1.43 (3H, s, IP), 1.45 (3H, s, IP), 1.52-1.60 
(2H, m), 1.65 (1H, ddddd, J = 13.0, 13.0, 13.0, 3.0, 3.0 Hz), 1.76 (1H, m), 1.90 (1H, dd, J = 12.0, 
3.0 Hz), 2.08 (1H, ddd, J = 13.5, 4.0, 2.5 Hz), 2.15 (1H, dq, J = 7.5, 1.5 Hz, H-16), 3.48 (1H, br, H-
15), 3.89 (1H, d, J = 2.5 Hz, H-14), 4.47 (1H, d, J = 12.0 Hz, OCH2Ph), 4.57 (1H, br, OH-15), 4.61 
(1H, d, J = 12.0 Hz, OCH2Ph), 7.28-7.33 (3H, m), 7.34-7.38 (2H, m).  
13C-NMR (150MHz, CDCl3): δ 12.95, 19.93, 22.18, 23.59, 26.59, 28.64, 28.85, 36.46, 38.41, 39.83, 
41.77, 72.20, 73.23, 73.36, 82.27, 83.97, 108.53, 127.96, 128.11, 128.57. 
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Diethyl 2-((3aR,4S,5S,6R,6aS,10aS)-6-((benzyloxy)methyl)-octahydro-2,2,5,6-tetramethyl-3aH-
naphtho[1-d][1,3]dioxol-4-yloxy)maleate (46) 
Diethyl 2-((3aR,4S,5S,6R,6aS,10aS)-6-((benzyloxy)methyl)-octahydro-2,2,5,6-tetramethyl-3aH-
naphtho[1-d][1,3]dioxol-4-yloxy)fumarate (47) 
 
 Secondary alcohol 34 (246 mg, 657 μmol) was dissolved in 1,2-dichloroethane (5.0 ml), and 
added potassium fluoride (1.6 g, 11.8 mmol) at 0 °C under argon atmosphere. Diethylester 
acetylene (530 μl, 3.28 mmol) was added, and the resulting mixture was stirred at 75 °C for 6 hours. 
Acetic acid (940 μl, 16.4 mmol) and water (5 ml) was added at 0 °C. The layers were separated, and 
the aqueous solution was extracted twice with dichloromethane (15 ml×2). The combined organic 
extracts were concentrated under reduced pressure, and the resulting residue was purified on silica 
gel column chromatography (BW820-MH 12 g, PhMe : Et2O = 20 : 1) to afford desired compound 
46 (267 mg, 491 μmol, 75%) and undesired compound 47 (267 mg, 491 μmol, 15%).  
 
Rf value of 46: 0.45 (PhMe : iPr2O = 6 : 1). 
[α]D26 +40° (c 1.15, MeOH). 
HRFAB-MS (m/z): 545.3084 [M+H]+; calcd for C31H44O8: 545.3114. 
1H-NMR (600MHz, CDCl3): δ 0.92 (3H, d, J = 7.0 Hz, Me-18), 1.18 (3H, s, Me-17), 1.23-1.31 (2H, 
m), 1.26 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.35 (3H, t, J = 7.5 Hz, CO2CH2CH3), 1.46 (3H, s, IP), 
1.49-1.74 (5H, m), 1.52 (3H, s, IP), 1.79 (1H, m), 2.29 (1H, dq, J = 7.0, 4.0 Hz, H-16), 3.22 (2H, s, 
H-6), 3.95 (1H, d, J = 6.5 Hz, H-14), 4.15 (2H, q, J = 7.0 Hz, CO2CH2CH3), 4.31 (1H, dq, J = 10.5, 
7.0 Hz, CO2CH2CH3), 4.33 (1H, dq, J = 10.5, 7.0 Hz, CO2CH2CH3), 4.42 (1H, dd, J = 6.5, 4.0 Hz, 
H-15), 4.42 (1H, d, J = 12.5 Hz, OCH2Ph), 4.46 (1H, d, J = 12.5 Hz, OCH2Ph), 5.23 (1H, s, H-2), 
7.27-7.37 (5H, m).  
13C-NMR (150MHz, CDCl3): δ 13.88, 14.21, 19.36, 21.29, 23.23, 26.38, 29.51, 29.77, 36.92, 38.55, 
39.14, 42.84, 60.32, 62.04, 73.27, 76.79, 79.90, 81.18, 83.45, 94.38, 108.93, 127.40, 127.43, 128.28, 
138.56, 161.16, 163.61, 166.08. 
 
Rf value of 47: 0.57 (PhMe : iPr2O = 6 : 1). 
[α]D27 +25° (c 0.79, MeOH). 
HRFAB-MS (m/z): 545.3119 [M+H]+; calcd for C31H44O8: 545.3114. 
1H-NMR (600MHz, CDCl3): δ 1.01 (3H, d, J = 7.0 Hz, Me-18), 1.18 (3H, s, Me-17), 1.22-1.35 (2H, 
m), 1.28 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.33 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.42 (6H, s, IP), 
1.46 (1H, m), 1.52 (1H, m), 1.57-1.73 (3H, m), 2.10 (1H, m), 2.30 (1H, dq, J = 7.0, 4.5 Hz, H-16), 
3.26 (1H, d, J = 10.0 Hz, H-6), 3.27 (1H, d, J = 10.0 Hz, H-6'), 4.05 (1H, d, J = 7.5 Hz, H-14), 4.19 
(2H, q, J = 7.0 Hz, CO2CH2CH3), 4.23 (1H, dq, J = 10.0, 7.0 Hz, CO2CH2CH3), 4.28 (1H, dq, J = 
10.0, 7.0 Hz, CO2CH2CH3), 4.43 (1H, d, J = 12.0 Hz, OCH2Ph), 4.49 (1H, d, J = 12.0 Hz, OCH2Ph), 
4.87 (1H, dd, J = 7.5, 4.5 Hz, H-15), 6.10 (1H, s, H-2), 7.24-7.36 (5H, m). 
13C-NMR (150MHz, CDCl3): δ 14.05, 14.24, 19.16, 21.11, 22.80, 26.39, 29.43, 29.91, 37.61, 39.57, 
40.27, 42.88, 60.21, 61.84, 73.25, 77.68, 81.99, 82.23, 83.72, 108.60, 109.29, 127.30, 127.34, 
128.22, 138.73, 154.52, 163.10, 164.56. 
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Diethyl 2-((3aR,4S,5S,6R,6aS,10aS)-octahydro-6-(hydroxymethyl)-2,2,5,6-tetramethyl-3aH-
naphtho[1-d][1,3]dioxol-4-yloxy)fumarate 
 
 A solution of desired compound 46 (248 mg,  456 μmol) in ethanol (4 ml) was added 5% 
palladium on activated carbon (48 mg). The mixture was vigorously stirred for 2 hours under 
hydrogen atmosphere. The mixture was filtered and the filtrate was concentrated under reduced 
pressure to afford crude primaty alcohol (223 mg, 456 μmol).  
 
Rf value: 0.30 (PhMe : iPr2O = 3 : 1). 
[α]D26 +25° (c 1.54, MeOH). 
HRFAB-MS (m/z): 455.2637 [M+H]+; calcd for C24H38O8: 455.2645. 
1H-NMR (600MHz, CDCl3): δ 0.97 (3H, s, Me-17), 1.08 (3H, d, J = 7.0 Hz, Me-18), 1.27 (3H, t, J 
= 7.0 Hz, CO2CH2CH3), 1.30-1.39 (2H, m), 1.35 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.46 (3H, s, IP), 
1.49 (3H, s, IP), 1.53-1.72 (4H, m), 1.76-1.89 (2H, m), 2.01 (1H, br), 2.11 (1H, m), 2.26 (1H, dq, J 
= 7.0, 2.0 Hz, H-16), 3.28 (1H, dd, J = 10.5, 6.0 Hz, H-6), 3.37 (1H, d, J = 10.5 Hz, H-6'), 3.96 (1H, 
d, J = 3.0 Hz, H-14), 4.11 (1H, br, H-15), 4.17 (2H, q, J = 7.0 Hz, CO2CH2CH3), 4.33 (1H, dq, J = 
10.0, 7.0 Hz, CO2CH2CH3), 4.35 (1H, dq, J = 10.0, 7.0 Hz, CO2CH2CH3), 5.41 (1H, s, H-2).  
13C-NMR (150MHz, CDCl3): δ 13.84, 14.14, 20.34, 21.80, 23.50, 26.27, 29.08, 35.60, 39.45, 60.69, 
62.43, 78.98, 81.96, 83.11, 96.88, 109.70, 162.83, 165.58. 
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Diethyl 2-[[(3aR,4S,5S,6R,6aS,10aS)-6-formyloctahydro-2,2,5,6-
tetramethyl-5H-naphtho[1,8a-d]-1,3-dioxol-4-yl]oxy]fumarate (6) 
 
 A mixture of primary alcohol (223 mg, 456 μmol) and neutral aluminu (292 mg) in 
dichloromethane (4.4 ml) was added pyridinium chlorochromate (147 mg, 682 μmol) under 
nitrogen atmosphere, and stirred at room temperature for 6 hours. The mixture was filtered through 
celite and washed twice with dichloromethane (2 ml×2). The filtrate was concentrated under 
reduced pressure, and the resulting residue was purified on silica gel column chromatography 
(BW820-MH 12 g, PhMe : EtOAc = 20 : 1) to afford aldehyde 6 (158 mg, 349 μmol, 77%). 
 
Rf value: 0.54 (PhMe : Et2O = 3 : 1). 
[α]D24 +23° (c 0.73, MeOH). 
HRFAB-MS (m/z): 453.2476 [M+H]+; calcd for C24H36O8: 453.2488. 
1H-NMR (600MHz, CDCl3): δ 0.99 (3H, d, J = 7.0 Hz, Me-18), 1.13 (3H, s, Me-17), 1.17 (1H, m), 
1.27 (1H, m), 1.28 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.36 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.43 
(1H, ddd, J = 13.5, 13.5, 2.5 Hz, H-12), 1.46 (3H, s, IP), 1.49 (3H, s, IP), 1.52-1.71 (3H, m), 1.76 
(1H, m), 2.02 (1H, dd, J = 12.5, 3.0 Hz, H-8), 2.14 (1H, ddd, J = 13.5, 4.5, 3.0 Hz, H-12), 2.20 (1H, 
dq, J = 7.0, 1.5 Hz, H-16), 4.11 (1H, d, J = 2.5 Hz, H-14), 4.15 (1H, dd, J = 2.5, 1.5 Hz, H-15), 4.17 
(2H, q, J = 7.0 Hz, CO2CH2CH3), 4.35 (1H, dq, J = 10.0, 7.0 Hz, CO2CH2CH3), 4.37 (1H, dq, J = 
10.0, 7.0 Hz, CO2CH2CH3), 5.39 (1H, s, H-2), 9.42 (1H, s, H-6).  
13C-NMR (150MHz, CDCl3): δ 13.12, 13.94, 14.16, 16.51, 21.82, 24.31, 26.09, 28.55, 28.72, 34.81, 
38.71, 41.15, 50.51, 60.61, 62.29, 78.28, 80.49, 81.62, 95.55, 110.27, 160.07, 163.11, 165.57, 
205.18. 
 
－56－ 
 
  
O
O
Me
Me
H
O
OH
CO2Et
CO2Et
48
 
 
(3aR,4S,9R,9aS,13aS,14S)-Octahydro-2,2,9,14-tetramethyl-8-oxy-4,9-
methano-1,3-dioxolo[4,5-m][3]benzoxonin-6,7-dicarboxylicacid-diethylester 
(48) 
 
 Aldehyde 6 (100 mg, 221 μmol) was dissolved in tetrahydrofuran (7 ml) under argon atmosphere, 
and added 1.0M solution of sodiumbis(trimethylsilyl)amide in tetrahydrofuran (330 μl, 330 μmol) 
at –78 °C. The mixture was stirred for 10 minutes, and then acetic acid (19 μl, 330 μmol) was added. 
The resulting mixture was concentrated under reduced pressure. Water (2.0 ml) and ethyl acetate 
(0.5 ml) was added and the layers were separated. The aqueous solution was extracted twice with 
ethyl acetate (2.0 ml×2). The combined organic extracts were concentrated to afford the residue 
which was purified on silica gel column chromatography (BW820-MH 600 g, PhMe : tBuOMe = 
6 : 1) to diastereomeric alcohol 48 (88.1 mg, 195 μmol, 88%). 
 
Less polar of  48. 
Rf value: 0.40 (PhMe : tBuOMe = 6 : 1). 
1H-NMR (600MHz, CDCl3): δ 1.12 (3H, s, Me-17), 1.28 (3H, t, J = 6.5 Hz, CO2CH2CH3), 1.32 (3H, 
t, J = 6.5 Hz, CO2CH2CH3), 1.35 (3H, d, J = 7.0 Hz, Me-18), 1.41 (1H, m), 1.46 (3H, s, IP), 1.46 
(3H, s, IP), 1.55 (1H, m), 1.61-1.69 (2H, m), 1.74 (1H, m), 1.81 (1H, m), 2.11 (1H, m), 2.20 (1H, dq, 
J = 7.0, 0.5 Hz, H-16), 4.01 (1H, d, J = 2.5 Hz, H-14), 4.20 (2H, m), 4.24 (2H, m), 4.28 (1H, dd, J = 
2.5, 0.5 Hz, H-15), 4.46 (1H, s, H-6).  
13C-NMR (150MHz, CDCl3): δ 13.90, 13.94, 16.82, 19.86, 21.72, 24.55, 26.38, 28.78, 29.18, 34.10, 
39.78, 41.14, 43.34, 61.44, 61.79, 75.75, 82.01, 82.47, 87.55, 110.04, 113.46, 150.99, 164.59, 
168.58. 
 
More polar of  48. 
Rf value of diastereomer: 0.28 (PhMe : tBuOMe = 6 : 1). 
1H-NMR (600MHz, CDCl3): δ 1.09 (3H, d, J = 7.5 Hz, Me-18), 1.25 (3H, s, Me-17), 1.27 (3H, t, J 
= 6.5 Hz, CO2CH2CH3), 1.31 (3H, t, J = 6.5 Hz, CO2CH2CH3), 1.32-1.45 (2H, m), 1.44 (3H, s, IP), 
1.47 (3H, s, IP), 1.53 (1H, m), 1.60-1.73 (3H, m), 1.80 (1H, dd, J = 11.5, 2.5 Hz, H-8), 2.07 (1H, m), 
2.20 (1H, m), 2.37 (1H, dq, J = 7.5, 0.0 Hz, H-16), 3.29 (1H, d, J = 4.0 Hz, OH-6), 3.97 (1H, d, J = 
2.5 Hz, H-14), 4.10 (1H, dd, J = 2.5, 0.0 Hz, H-15), 4.19 (2H, m), 4.21 (1H, d, J = 4.0 Hz, H-6), 
4.23 (2H, m).  
13C-NMR (150MHz, CDCl3): δ 13.86, 14.59, 20.95, 22.07, 26.29, 27.24, 28.83, 29.11, 29.19, 33.18, 
39.24, 41.59, 42.11, 61.55, 61.72, 77.53, 81.74, 83.36, 85.79, 109.53, 114.84, 150.83, 164.54, 
168.68. 
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(3aR,4S,9R,9aS,13aS,14S)-Octahydro-2,2,9,14-tetramethyl-8-oxo-4,9-
methano-8H-1,3-dioxolo[4,5-m][3]benzoxonin-6,7-dicarboxylicacid-
diethylester (49) 
 
 A solution of diastereomeric alcohol 48 (88.1 mg, 195 μmol) in toluene (1.7 ml) was added a 
solution of 0.45M solution of o-iodoxybenzoic acid in dimethylsulfoxide (870 μl, 390 μmol) under 
argon atmosphere, and left at room temperature for 3 hours. 20% aqueous sodium thiosulfate (500 
μl) was added, and the resulting layers were separated. The aqueous solution was extracted twice 
with toluene (1.5 ml×2). The combined organic extracts were concentrated to afford the residue 
which was purified on silica gel column chromatography (BW820-MH 4.4 g, PhMe : EtOAc = 9 : 
1) to ketone 49 (81.0 mg, 180 μmol, 73%). 
 
Rf value: 0.40 (PhMe : EtOAc = 9 : 1). 
[α]D23 +51° (c 0.84, MeOH). 
HRFAB-MS (m/z): 451.2319 [M+H]+; calcd for C24H34O8: 451.2332. 
1H-NMR (600MHz, CDCl3): δ 1.06 (3H, d, J = 7.5 Hz, Me-18), 1.21 (3H, s, Me-17), 1.22-1.38 (2H, 
m), 1.31 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.34 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.42 (1H, m), 1.48 
(3H, s, IP), 1.49 (3H, s, IP), 1.52-1.68 (4H, m), 1.75 (1H, m), 2.16 (1H, m), 2.46 (1H, dq, J = 7.5, 
0.5 Hz, H-16), 4.18 (1H, d, J = 2.5 Hz, H-14), 4.25 (1H, dq, J = 10.5, 7.0 Hz, CO2CH2CH3), 4.28 
(1H, dq, J = 10.5, 7.0 Hz, CO2CH2CH3), 4.48 (1H, dd, J = 2.5, 0.5 Hz, H-15).  
13C-NMR (150MHz, CDCl3): δ 13.88, 13.93, 14.87, 17.05, 21.58, 24.28, 25.96, 28.73, 29.07, 31.13, 
40.98, 41.07, 53.08, 61.69, 62.81, 80.71, 82.21, 85.27, 110.64, 120.22, 150.79, 163.11, 165.85, 
198.72. 
 
 
  
O
O
Me
Me
H
O
O
CO2Et
O
OH
51
 
(3aR,4S,9R,9aS,13aS,14S)-Octahydro-2,2,9,14-tetramethyl-8-oxo-4,9-
methano-8H-1,3-dioxolo[4,5m][3]benzoxonin-6,7-dicarboxylicacid-7-
ethylester (51) 
 
 A mixture of ketone 49 (81.0 mg, 180 μmol) in 50% aqueous tetrahydrofurane (2.7 ml) was 
added sodium carbonate (72.8 mg, 687 μmol), and stirred at room temperature for 3 hours. The 
mixture was concentrated to afford the residue which was purified on silica gel column 
chromatography (BW820-MH 4.0 g, n-butanol : EtOH : CHCl3 = 8 : 1 : 1) to hydolysis 51 (70.0 mg, 
166 μmol, 93%). 
 
Rf value: 0.46 (n-butanol : EtOH : CHCl3 = 8 : 1 : 1). 
1H-NMR (600MHz, CDCl3): δ 0.93 (3H, d, J = 7.5 Hz, Me-18), 1.02 (1H, m), 1.20 (3H, t, J = 7.0 
Hz, CO2CH2CH3), 1.26 (3H, s, IP), 1.28 (3H, s, IP), 1.36 (3H, s, Me-17), 1.49-1.58 (2H, m), 1.63 
(1H, m), 1.76 (1H, m), 1.85 (1H, m), 2.40 (1H, dq, J = 7.0, 0.0 Hz, H-16), 3.96 (1H, m, H-14), 4.33 
(1H, dd, J = 2.5, 0.5 Hz, H-15), 4.39 (1H, m, CO2CH2CH3). 
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(3aR,4S,9R,9aS,13aS,14S)-Octahydro-2,2,9,14-tetramethyl-8-oxo-4,9-
methano-8H-1,3-dioxolo[4,5m][3]benzoxonin-6,7-dicarboxylicacid-6-
ehylthio-7-ethylester (54) 
 
 
 A mixture of hydolysis 51 (30.0 mg, 71.1 μmol), 1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide hydrochloride (41.0 mg, 213 μmol) and pyridine (17 μl, 213 μmol) in dichloromethane (900 
μl) was added ethanethiol (26 μl, 355 μmol) under argon atmosphere, and left at room temperature 
for 1 hour. The mixture was concentrated to afford the residue which was purified on silica gel 
column chromatography (BW820-MH 1.5 g, PhMe : iPr2O = 7 : 1) to thioester 54 (21.9 mg, 46.9 
μmol, 66%). 
 
Rf value: 0.41 (PhMe : iPr2O = 6 : 1). 
[α]D22 –2.0° (c 1.47, MeOH). 
HRFAB-MS (m/z): 467.2098 [M+H]+; calcd for C24H34O7S: 467.2104. 
1H-NMR (600MHz, CDCl3): δ 1.08 (3H, d, J = 7.5 Hz, Me-18), 1.21 (3H, s, Me-17), 1.25 (1H, m), 
1.28 (3H, t, J = 7.0 Hz, SCH2CH3), 1.32 (3H, t, J = 7.0 Hz, CO2CH2CH3), 1.35 (1H, dddd, J = 13.5, 
13.5, 13.5, 3.5 Hz), 1.42 (1H, m), 1.49 (3H, s, IP), 1.50 (3H, s, IP), 1.56 (1H, m), 1.58-1.69 (3H, m), 
1.75 (1H, m), 2.17 (1H, m), 2.49 (1H, dq, J = 7.5, 0.0 Hz, H-16), 2.90 (1H, dq, J = 13.0, 7.0 Hz, 
SCH2CH3), 2.92 (1H, dq, J = 13.0, 7.0 Hz, SCH2CH3), 4.21 (1H, d, J = 2.5 Hz, H-14), 4.31 (1H, dq, 
J = 10.5, 7.0 Hz, CO2CH2CH3), 4.33 (1H, dq, J = 10.5, 7.0 Hz, CO2CH2CH3), 4.51 (1H, dd, J = 2.5, 
0.0 Hz, H-15).  
13C-NMR (150MHz, CDCl3): δ 13.90, 14.98, 17.05, 21.57, 23.68, 24.14, 25.92, 28.70, 29.03, 31.33, 
40.70, 41.04, 53.05, 61.71, 80.98, 82.06, 85.31, 110.69, 117.51, 151.00, 165.37, 190.36, 198.79. 
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(3aS,7aS,8R,14S,14aR,15S)-Hexahydro-12-hydroxy-2,2,8,15-tetramethyl-8,14-
methano-4H-1,3-dioxolo[4,5-m]furo[3,4-d][3]benzoxonin-9,10(5H,12H)-dione 
(55) 
 
 To a stirred mixture of thioester 54 (10.1 mg, 21.7 μmol) and Lindlar catalyst (41.8 mg, 21.7 
μmol) in acetone (300 μl) was added triethylsilane (21 μl, 130 μmol) under argon atmosphere, and 
stirred at room temperature for 30 minutes. The mixture was filtered, and the filtrate was 
concentrated under reduced pressure. The resulting residue was purified on silica gel column 
chromatography (BW820-MH 1.0 g, CHCl3 : EtOAc = 1 : 1) to afford diastereomeric lactol 55 (6.5 
mg, 17.1 μmol, 80%). 
 
Rf value: 0.20 ( CHCl3  : methyl ethyl ketone = 4 : 1). 
HRFAB-MS (m/z): 379.1764 [M+H]+; calcd for C20H26O7: 379.1757. 
1H-NMR (600MHz, CDCl3): δ 1.00 (3H, d, J = 7.5 Hz, Me-18), 1.03 (3H, d, J = 7.5Hz, Me-18), 
1.56 (1H, m), 1.21 (6H, s, Me-17), 1.23-1.32 (2H, m), 1.35-1.48 (4H, m), 1.49 (12H, s, IP), 1.53-
1.72 (7H, m), 1.75 (1H, m), 1.89 (1H, m), 2.19 (1H, m), 2.23 (1H, m), 2.49 (1H, dq, J = 7.5, 1.5 Hz, 
H-16), 2.50 (1H, dq, J = 7.5, 1.5 Hz, H-16), 4.23 (1H, d, J = 1.5 Hz, H-14), 4.29 (1H, d, J = 1.5 Hz, 
H-14), 4.66 (1H, dd, J = 1.5, 1.5 Hz, H-15), 4.73 (1H, dd, J = 1.5, 1.5 Hz, H-15), 5.81 (2H, br), 5.90 
(1H, s, H-4), 5.95 (1H, s, H-4). 
－59－ 
13C-NMR (150MHz, CDCl3): δ 13.79, 14.18, 16.76, 21.31, 21.35, 24.58, 25.53, 25.95, 29.0129.06, 
29.14, 30.90, 30.95, 40.65, 40.94, 42.26, 43.14, 53.23, 53.28, 79.71, 79.90, 82.52, 82.56, 87.77, 
87.93, 92.86, 92.92, 100.80, 100.81, 110.86, 111.03, 168.44, 168.60, 176.70, 176.76, 195.10, 
195.20. 
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(3aS,7aS,8R,14S,14aR,15S)-Hexahydro-2,2,8,15-tetramethyl-8,14-methano-4H-
1,3-dioxolo[4,5-m]furo[3,4-d][3]benzoxonin-9,10(5H,12H)-dione (50) 
 Diastereomeric lactol 55 (5.1 mg, 13.5 μmol) was dissolved 0.28M solution of 
triphenylphosphine in dichloromethane (193 μl, 54.0 μmol) under argon atmosphere. 0.21M 
solution of carbon tetrabromide in dichloromethane (193 μl, 40.5 μmol) was added, and the 
resulting solution was left at 0 °C for 30 minutes. The solution was concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 510 mg, PhMe : 
methyl ethyl ketone = 4 : 1) to lactone 50 (3.7 mg, 10.2 μmol, 76%). 
 
Rf value: 0.50 (CHCl3  : methyl ethyl ketone = 4 : 1). 
[α]D27 +120° (c 0.76, MeOH). 
HRFAB-MS (m/z): 363.1808 [M+H]+; calcd for C20H26O6: 363.1807. 
1H-NMR (600MHz, CDCl3): δ 1.01 (3H, d, J = 7.5 Hz, Me-18), .14 (1H, ddddd, J = 12.5, 12.5, 12.5, 
3.5, 3.5 Hz,), 1.23 (3H, s, Me-17), 1.27 (1H, ddd, J = 13.5, 13.5, 3.5 Hz,), 1.45 (1H, m), 1.50 (6H, s, 
IP), 1.56 (1H, m), 1.59-1.70 (3H, m), 1.77 (1H, m), 2.23 (1H, ddd, J = 14.0, 4.0, 2.5 Hz), 2.51 (1H, 
dq, J = 7.5, 1.5 Hz, H-16), 4.19 (1H, d, J = 1.5 Hz, H-14), 4.60 (1H, d, J = 16.5 Hz, H-4), 4.61 (1H, 
dd, J = 1.5, 1.5 Hz, H-15), 4.66 (1H, d, J = 16.5 Hz, H-4'). 
13C-NMR (150MHz, CDCl3): δ 14.20, 16.77, 21.37, 24.48, 26.00, 29.02, 29.13, 30.94, 41.05, 43.12, 
53.06, 65.80, 79.84, 82.64, 87.59, 101.01, 111.02, 169.01, 178.69, 193.90. 
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(5S,6R,6aS,10aS,11R,13S)-Octahydro-6,6a-dihydroxy-11,13-dimethyl-5,11-
methanofuro[3,4-d][3]benzoxonin-1,12(3H,5H)-dione (59) 
 
 
 Lactone 50 (2.8 mg, 7.7 μmol) was added 70% aqueous trifluoroacetic acid (300 μl) and left at 
50 °C for 13 hours. The solution was concentrated to afford the residue which was purified on silica 
gel column chromatography (BW820-MH 560 mg, CHCl3 : methyl ethyl ketone = 1 : 1) to di-ol 59 
(1.7 mg, 5.3 μmol, 69%). 
 
Rf value: 0.16 (CHCl3 : methyl ethyl ketone = 2 : 1). 
[α]D27 +97° (c 0.43, MeOH).  
HRFAB-MS (m/z): 323.1490[M+H]+; calcd for C17H22O6: 323.1495. 
 
 
 
–60– 
1H-NMR (600MHz, Acetone-d6): δ 0.96 (3H, d, J = 7.0 Hz, Me-18), 1.10 (1H, ddddd, J = 12.5, 
12.5, 12.5, 3.0, 3.0 Hz), 1.17 (3H, s, Me-17), 1.22 (1H, ddd, J = 13.0, 13.0, 3.5 Hz), 1.29 (1H, m), 
1.43 (1H, m), 1.52-1.73 (4H, m), 2.03-2.08 (2H, m), 2.75 (1H, dq, J = 7.0, 3.0 Hz, H-16), 3.36 (1H, 
s, OH-13), 3.70 (1H, d, J = 6.5 Hz, H-14), 4.63 (1H, d, J = 16.0 Hz, H-4), 4.66 (1H, d, , J = 16.0 Hz, 
H-4'), 4.80 (1H, d, J = 3.0 Hz, H-15), 5.02 (1H, d, J = 6.5 Hz, OH-14). 
13C-NMR (150MHz, Acetone-d6): δ 13.44, 17.91, 21.66, 24.47, 26.74, 33.33, 39.98, 43.17, 53.58, 
66.45, 69.24, 79.24, 93.43, 101.32, 178.73, 194.84. 
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(−)-Tetrodecamycin (1)
 
 
(5S,6R,6aS,10aS,11R,13S)-Octahydro-6,6a-dihydroxy-11,13-dimethyl-3-
methylene-5,11-methanofuro[3,4-d][3]benzoxonin-1,12(3H,5H)-dione,  
(–)-tetrodecamycin (1) 
 
 Di-ol 59 (2.1 mg, 6.5 μmol) was dissolved 0.46M solution of diisoprorylethylamine in dioxane 
(100 μl, 46.0 μmol) under argon atmosphere, and added Eschenmoser's salt (3.8 mg, 20.5 μmol). 
The mixture was stirred at room temperature for 10 hours. 2.6M solution of methyl iodide in 
dioxane (50 μl, 130 μmol) was added and stirred at room temperature for 11 hours. The mixture was 
concentrated to afford the residue which was purified on silica gel column chromatography 
(BW820-MH 420 mg, PhMe : EtOAc = 1 : 1) to (–)-tetrodecamycin (1) (1.1 mg, 3.3 μmol, 50%). 
 
Rf value: 0.46 (PhMe : EtOAc = 1 : 2). 
[α]D26 –6.0 (c 0.42, MeOH) [natural [α]D23 –6.0 (c 0.50, MeOH)].  
HRFAB-MS (m/z): 334. [M+H]+; calcd for C18H22O6: 334.  
1H-NMR (600MHz, CDCl3): δ 1.01 (3H, d, J = 7.5 Hz, Me-18), 1.12 (1H, ddddd, J = 13.0, 13.0, 
13.0, 3.0, 3.0 Hz, H-10), 1.25 (3H, s, Me-17), 1.25 (1H,  , H-12), 1.34 (1H, dd, J = 12.5, 4.0 Hz, 
H-8), 1.43 (1H, ddddd, J = 13.0, 13.0, 13.0, 3.0, 3.0 Hz, H-11), 1.50 (1H, m, H-9), 1.60 (2H, m, H-9 
& H-11), 1.79 (1H, m, H-10), 2.04 (1H, s, OH-13), 2.09 (1H, ddd, J = 14.0, 5.0, 2.5 Hz, H-12), 2.65 
(1H, dq, J = 7.5, 3.0 Hz, H-16), 3.08-3.16 (1H, brs, OH-14), 3.61 (1H, brs, H-14), 4.81 (1H, dd, J = 
3.0, 0.5 Hz, H-15), 5.27 (1H, d, J = 2.5 Hz, H-5), 5.37 (1H, d, J = 2.5 Hz, H-5').  
13C-NMR (150MHz, CDCl3): δ 13.6, 17.56, 20.87, 23.52, 25.73, 32.72, 39.70, 42.84, 53.10, 69.01, 
78.57, 92.00, 96.40, 100.79, 148.39, 164.64, 164.64, 194.53.  
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1H-NMR spectrum of 9 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 9 (150MHz, CDCl3) 
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1H-NMR spectrum of 15 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 15 (150MHz, CDCl3) 
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1H-NMR spectrum of 16 (600MHz, CDCl3) 
 
13C-NMR spectrum of 16 (150MHz, CDCl3) 
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1H-NMR spectrum of 8 (600MHz, CDCl3) 
 
 
 
13C-NMR spectrum of 8 (150MHz, CDCl3) 
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1H-NMR spectrum of 23 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 23 (150MHz, CDCl3) 
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1H-NMR spectrum of benzyl compound (600MHz, CDCl3) 
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1H-NMR spectrum of 24 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 24 (150MHz, CDCl3) 
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1H-NMR spectrum of 27 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 27 (150MHz, CDCl3) 
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1H-NMR spectrum of 28 (600MHz, CDCl3) 
 
13C-NMR spectrum of 28 (150MHz, CDCl ) 3
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1H-NMR spectrum of 29 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 29 (150MHz, CDCl3) 
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1H-NMR spectrum of 7 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 7 (150MHz, CDCl3) 
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1H-NMR spectrum of 31 (600MHz, CDCl3) 
 
13C-NMR spectrum of 31 (150MHz, CDCl ) 3
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1H-NMR spectrum of 34 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 34 (150MHz, CDCl3) 
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1H-NMR spectrum of 46 (600MHz, CDCl3) 
 
13C-NMR spectrum of 46 (150MHz, CDCl ) 3
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1H-NMR spectrum of 47 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 47 (150MHz, CDCl3) 
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1H-NMR spectrum of primary alcohol from 46 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of primary alcohol from 46 (150MHz, CDCl3) 
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1H-NMR spectrum of 6 (600MHz, CDCl3) 
 
13C-NMR spectrum of 6 (150MHz, CDCl ) 3
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1H-NMR spectrum of 48 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 48 (150MHz, CDCl3) 
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HMBC of 48 (600MHz, CDCl3) 
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1H-NMR spectrum of 48’ (600MHz, CDCl3) 
 
 
 
13C-NMR spectrum of 48’ (150MHz, CDCl3) 
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1H-NMR spectrum of 49 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 49 (150MHz, CDCl3) 
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1H-NMR spectrum of 51 (600MHz, CDCl3) 
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1H-NMR spectrum of 54 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 54 (150MHz, CDCl3) 
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1H-NMR spectrum of 55 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 55 (150MHz, CDCl3) 
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1H-NMR spectrum of 50 (600MHz, CDCl3) 
 
 
13C-NMR spectrum of 50 (150MHz, CDCl3) 
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1H-NMR spectrum of 59 (600MHz, Acetone-d6) 
 
 
13C-NMR spectrum of 59 (150MHz, Acetone-d6) 
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1H-NMR spectrum of synthetic (–)-tetrodecamycin (1) (600MHz, CDCl3) 
 
 
1H-NMR spectrum of synthetic (–)-tetrodecamycin (1) (600MHz, CDCl3) 
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13C-NMR spectrum of synthetic (–)-tetrodecamycin (1) (150MHz, CDCl3) 
 
 
MASS spectrum of synthetic (–)-tetrodecamycin (1) (FAB+) 
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1H-NMR spectrum of natural (–)-tetrodecamycin (1) (600MHz, CDCl3) 
 
 
1H-NMR spectrum of natural (–)-tetrodecamycin (1) (600MHz, CDCl3) 
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2. Total Synthesis and Structural Determination of Actinopyrone A 
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5-(3-Methylbut-3-enylthio)-1-phenyl-1H-tetrazole (82) 
 
 A mixture of 3-methyl-3-butene-1-ol (80) (131 μl, 1.30 mmol), 1-phenyl-1H-tetra-5-thiol (81) 
(178 mg, 1.00 mmol) and triphenylphosphine (341 mg, 1.30 mmol) in tetrahydrofuran (2.7 ml) was 
added 2.2M solution of diethyl azodicarboxylate in toluene (590 μl, 1.30 mmol) at 0 °C under argon 
atmosphere, and stirred for 2 hours. The mixture was concentrated to afford the residue which was 
purified on silica gel column chromatography (BW820-MH 20 g, hexane : EtOAc = 6 : 1) to 
thioether 82 (226 mg, 917 μmol, 92%). 
 
Rf value: 0.28 (hexane : EtOAc = 6 : 1). 
1H-NMR (400 MHz, CDCl3) δ 1.77 (3H, s, Me-8), 2.54 (2H, t, J=13.0 Hz, H-9), 3.54 (2H, t, J=13.0 
Hz, H-10), 4.78 (1H, m, H-7), 4.84 (1H, m, H-7'),  7.51-7.64 (5H, m, Ph). 
13C-NMR (100 MHz, CDCl3) δ 22.0, 31.4, 36.8, 77.2, 112.4, 123.8, 129.8, 130.1, 133.7, 142.5, 
154.3. 
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5-(2-(2-Methyloxiran-2-yl)ethylsulfonyl)-1-phenyl-1H-tetrazole (78) 
 
 A mixture of thioether 82 (2.52 g, 10.1 mmol) and sodium bicarbonate (3.04 g, 36.2 mmol) in 
dichloromethane (25 ml) was added m-chloroperbenzoic acid (6.12 g, 35.5 mmol) which was 
dissolved in dichloromethane (75 ml) at 0 °C under argon atmosphere, and stirred for 1 hour. 
Sodium bicarbonate (0.85 g, 10.1 mmol) and m-chloroperbenzoic acid (1.75 g, 10.1 mmol) which 
was dissolved in dichloromethane (20 ml) was added. The mixture was warmed to room 
temperature and stirred for 71 hours. Dichloromethane (100 ml) was added and washed with 1.0M 
aqueous sodium thiosulfate (45 ml), 1.0M aqueous sodium carbonate (45 ml), water (40 ml) and 
brine (40 ml), subsequently. The resulting mixture was concentrated to afford the residue which was 
purified on silica gel column chromatography (BW820-MH 200 g, hexane : EtOAc = 2 : 1) to 
epoxide 78 (2.54 g, 8.63 mmol, 86%). 
 
Rf value: 0.24 (hexane : EtOAc = 2 : 1). 
prisms recrystallized from iso-propanol, mp 88.3-88.7 °C. 
HRFAB-MS (m/z): 295.0863 [M+H]+; calcd for C12H15O3N4S1: 295.0865.  
1H-NMR (400 MHz, CDCl3) δ 1.40 (3H, s, Me-8), 2.21 (1H, ddd, J=14.4, 10.8, 5.4 Hz, H-9), 2.32 
(1H, ddd, J=14.4, 10.8, 5.6 Hz, H-9'), 2.66 (1H, d, J=4.0 Hz, H-7), 2.71 (1H, d, J=4.0 Hz, H-7'), 
3.75 (1H, ddd, J=14.8, 10.8, 5.4 Hz, H-10), 3.83 (1H, ddd, J=14.8, 10.8, 5.6 Hz, H-10'), 7.56-7.64 
(3H, m, Ph), 7.65-7.73 (2H, m, Ph).  
13C-NMR (100 MHz, CDCl3) δ 21.0, 28.9, 52.1, 53.3, 54.8, 125.1, 129.8, 131.5, 133.0, 153.3. 
Anal. calcd for C12H14O3N4S1: C 48.97, H 4.79, N 19.04, found: C 48.92, H 4.78, N 18.91. 
IR (KBr) 3072, 3056, 2981, 2967, 2927, 1949, 1348, 1324, 1155, 894, 765, 694.  
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84 2-(Chloromethyl)-6-methoxy-3,5-dimethyl-4H-pyran-4-one (84) 
 
 A solution of 2-methoxy-γ-pyrone (73) (320 mg, 2.50 mmol) in tetrahydrofuran (8.4 ml) was 
added 1.06M solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (3.07 ml, 3.25 mmol) 
at –78 °C under argon atmosphere. N-Chlorosuccinimide (0.85 g, 10.1 mmol) which was dissolved 
in tetrohydrofuran (20 ml) was added, and the resulting mixture was stirred for 1 hour. The mixture 
was concentrated, then ethyl acetate (300 ml) and water (10 ml) was added. The layers were 
separated, and the aqueous solution was extracted twice with ethyl acetate. The combined organic 
extracts were washed with saturated aqueous sodium bicarbonate (10 ml×2) and brine (10 ml), 
subsequently. The organic extracts were concentrated to afford the residue which was purified on 
silica gel column chromatography (BW820-MH 50 g, hexane : EtOAc = 1 : 1) to chloride 84 (338 
mg, 1.67mmol, 67%). 
 
Rf value: 0.19 (hexane : EtOAc = 1 : 1). 
1H-NMR (400 MHz, CDCl3) δ 1.86 (3H, s, Me), 2.04 (3H, s, Me), 4.01 (3H, s, OMe), 4.45 (2H, s, 
H-6). 
13C-NMR (100 MHz, CDCl3) δ 7.0, 9.8, 39.4, 55.6, 100.4, 121.4, 151.7, 162.2, 180.2. 
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79 Diethyl (6-methoxy-3,5-dimethyl-4-oxo-4H-pyran-2-yl)methylphosphonate (79) 
 
 Chloride 84 (141 mg, 695 μmol) was dissolved in triethoxy phosphine (2.1 ml, 12.2 mmol) under 
argon atmosphere, and stirred at 140 °C for 6.5 hours. The mixture was concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 20 g, PhMe : 
acetone = 3 : 2) to phosphine 79 (169 mg, 555 μmol, 80%). 
 
Rf value: 0.19 (PhMe : acetone = 1 : 1). 
prisms recrystallized from iPrO, mp 70.0-70.4 °C. 
HRFAB-MS (m/z): 305.1158 [M+H]+; calcd for C13H22O6P1: 305.1154.  
1H-NMR (400 MHz, CDCl3) δ 1.32 (6H, t, J=7.1 Hz), 1.85 (3H, s), 1.98 (3H, d, J=3.7 Hz), 3.14 
(2H, d, J=22.0 Hz), 3.99 (3H, s), 4.08-4.17 (4H, m). 
13C-NMR (100 MHz, CDCl3) δ 6.9, 10.4 (d, J=3 Hz), 16.5 (d, J=6 Hz), 30.1 (d, J=140 Hz), 55.7, 
62.6 (d, J=6 Hz), 99.8, 120.8 (d, J=9 Hz), 149.4 (d, J=12 Hz), 162.3, 180.4 (d, J=3 Hz). 
IR (KBr) 2985, 2967, 2927, 1672, 1602, 1463, 1328, 1253, 1238, 1020, 977, 792.  
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3-((2E,4R,5R,6E)-5-Hydroxy-2,4,6-trimethyl-1-oxo-2,6-octadienyl)-4-(1-methylethyl)-2-
oxazolidinone (86) 
 
 A mixture of oxazolidone 77 (5.26 g, 15.5 mmol) and trans-2-methyl-2-butenal (65) (2.24 ml, 
23.2 mmol) in dichloromethane (50 ml) was added titanium tetrachloride (1.78 ml, 16.3 mmol) 
which was dissolved in dichloromethane (152 ml) at –78 °C under argon atmosphere. The resulting 
mixture was stirred at –60 °C for 17 hours. Pyridine (1.3 ml,mmol) was added at 0 °C, and the 
resulting mixture was puored intosaturated aqueous sodium bicarbonate (100 ml). The mixture was 
filtered through Celite, and the filtrate was separated. The aqueous solution was extracted with 
chloroform (50 ml) and the combined organic extracts were washed with brine (30 ml). The organic 
extracts were concentrated to afford the residue which was purified on silica gel column 
chromatography (BW820-MH 500 g, hexane : EtOAc = 3 : 1) to anti-adduct 86 (3.89 g, 12.6 mmol, 
82%). 
 
Rf value: 0.23 (hexane : EtOAc = 2 : 1). 
[α]D25 +16.5° (c 1.16, CH2Cl2). 
1H-NMR (400 MHz, CDCl3) δ 0.82 (3H, d, J=6.6 Hz, Me-14), 0.92 (3H, d, J=7.1 Hz, iPr), 0.93 (3H, 
d, J=7.1 Hz, iPr), 1.63 (3H, d, J=6.6 Hz, Me-18), 1.66 (3H, d, J=1.2 Hz, Me-16), 1.97 (3H, d, J=1.2 
Hz, Me-12), 2.34 (1H, dqq, J=7.1, 7.1, 4.7 Hz, iPr), 2.74 (1H, ddq, J=10.3, 9.3, 6.6 Hz, H-14), 3.31 
(1H, d, J=1.7 Hz, OH-15), 3.66 (1H, dd, J=9.3, 1.7 Hz, H-15), 4.18 (1H, dd, J=9.0, 5.6 Hz), 4.34 
(1H, dd, J=9.0, 9.0 Hz), 4.57 (1H, ddd, J=9.0, 5.6, 4.7 Hz), 5.47 (1H, q, J=6.6 Hz, H-17), 5.78 (1H, 
dd, J=10.3, 1.2 Hz, H-13). 
13C-NMR (100 MHz, CDCl3) δ 10.4, 13.1, 14.0, 15.2, 16.1, 17.8, 28.4, 37.8, 58.1, 63.4, 77.2, 82.2, 
123.6, 131.7, 134.8, 142.0, 154.5, 171.5. 
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3-((2E,4R,5R,6E)-5-(((1,1-Dimethylethyl)dimethylsilyl)oxy)-2,4,6-trimethyl-1-oxo-2,6-octadienyl)-
4-(1-methylethyl)-2-oxazolidinone (87) 
 
 
 A mixture of anti-adduct 86 (3.01 g, 9.78 mmol) and 2,6-lutidine (1.71 ml, 14.7 mmol) in 
dichloromethane (60 ml) was added t-butyldimethylsilyl trifluoromethanesulfonyl (2.23 ml, 12.7 
mmol) at 0 °C under argon atmosphere, and the resulting mixture was stirred for 1 hour. t-
Butyldimethylsilyl trifluoromethanesulfonyl (171 μl, 977 μmol) was added, and the mixture was 
stirred for 30 minutes. Water (20 ml) was added at 0 °C, and the layer of mixture was separated. 
The aqueous solution was extracted with dichloromethane (20 ml) and the combined organic 
extracts were washed with brine (20 ml). The organic extracts were concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 120 g, hexane : 
EtOAc = 10 : 1) to silyl compound 87 (3.85 g, 9.12 mmol, 93%). 
 
－93－ 
Rf value: 0.55 (hexane : EtOAc = 3 : 1). 
[α]D22 –14.5° (c 1.16, CH2Cl2). 
1H-NMR (400 MHz, CDCl3) δ –0.06 (3H, s, SiMe), 0.01 (3H, s, SiMe), 0.84 (9H, s, SitBu), 0.84 
(3H, d, J=7.5 Hz, Me-14), 0.89 (3H, d, J=7.5 Hz, iPr), 0.91 (3H, d, J=7.5 Hz, iPr), 1.56 (3H, s, Me-
16), 1.59 (3H, d, J=6.7 Hz, Me-18), 1.92 (3H, d, J=1.8 Hz, Me-12), 2.39 (1H, dqq, J=7.5, 7.5, 4.7 
Hz, iPr), 2.64 (1H, ddq, J=10.1, 7.5, 7.5 Hz, H-14), 3.76 (1H, d, J=7.5 Hz, H-15), 4.17 (1H, dd, 
J=9.2, 4.7 Hz), 4.29 (1H, dd, J=9.2, 9.2 Hz), 4.47 (1H, ddd, J=9.2, 4.7, 4.7 Hz), 5.36 (1H, q, J=6.7 
Hz, H-17), 5.93 (1H, dd, J=10.1, 1.8 Hz, H-13). 
13C-NMR (100 MHz, CDCl3) δ –5.1, –4.8, 11.0, 12.9, 14.2, 14.9, 16.5, 17.9, 18.1, 25.8, 28.2, 37.8, 
58.4, 63.4, 82.7, 121.7, 130.8, 136.7, 142.3, 153.4, 171.8. 
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71  (2Z,4R,5R,6E)-5-Hydroxy-2,4,6-trimethylocta-2,6-dienal (71) 
 
 A solution of silyl compound 87 (1.41 g, 2.70 mmol) in dichloromethane (23 ml) was added 
0.99M solution of diisopropylaluminium hydride in toluene (4.09 ml, 4.05 mmol) which was 
dissolved in dichloromethane (123 ml) at –78 °C under argon atmosphere. The resulting mixture 
was stirred for 2 hours. Methanol (3.0 ml) and sodium sulfate decahydrate were added, and the 
mixture was stirred for 1 hour. The mixture was filtered through Celite, and the filtrate was 
concentrated to afford the residue which was purified on silica gel column chromatography 
(BW820-MH 50 g, hexane : EtOAc = 10 : 1) to aldehyde 71 (545 mg, 1.84 mmol, 68%). 
 
Rf value: 0.44 (hexane : EtOAc = 10 : 1). 
[α]D23 +9.60° (c 0.50, CH2Cl2). 
1H-NMR (400 MHz, CDCl3) δ –0.07 (3H, s, SiMe), –0.03 (3H, s, SiMe), 0.81 (9H, s, SitBu), 0.89 
(3H, d, J=6.7 Hz, Me-14), 1.57 (3H, s, Me-16), 1.60 (3H, d, J=6.7 Hz, Me-18), 1.75 (3H, d, J=1.3 
Hz, Me-12), 2.85 (1H, ddq, J=10.1, 8.0, 6.7 Hz, H-14), 3.81 (1H, d, J=8.0 Hz, H-15), 5.40 (1H, q, 
J=6.7 Hz, H-17), 6.36 (1H, dd, J=10.1, 1.3 Hz, H-13), 9.40 (1H, s, H-11). 
13C-NMR (100 MHz, CDCl3) δ –5.1, –4.7, 9.5, 10.9, 13.0, 16.5, 18.1, 25.7, 38.4, 82.8, 122.3, 136.3, 
139.0, 158.8, 195.6. 
 
 
Me
MeMeMe Me
OTBS
O
88  
((2E,4R,5R,6Z,8E)-3,5,7-Trimethyl-10-(2-methyloxiran-2-yl)deca-2,6,8-trien-4-yloxy)(tert-
butyl)dimethylsilane (88) 
 
 A solution of epoxide 78 (83.6 mg, 284 μmol) in dimethoxyethane (420 μl) was added 0.99M 
sodiumbis(trimethylsilyl)amide in tetrahydrofuran (273 μl, 270 μmol) at –78 °C under argon 
atmosphere, and the resulting mixture was stirred at –60 °C for 30 minutes. Aldehyde 71 (42.1 mg, 
142 μmol) which was dissolved in dimethoxyethane (600 μl) was added, and the stirring mixture 
was warmed to room temperature over 4.5 hours. Ethyl acetate (5.0 ml) and water (2.5 ml) was 
added, and the layer was separated. The aqueous solution was extracted with ethyl acetate (3.0 ml)  
and the combined organic extracts were washed with brine (2.5 ml). The organic extracts were 
concentrated to afford the residue which was purified on silica gel column chromatography 
(BW820-MH 9 g, hexane : EtOAc = 25 : 1) to triene 88 (43.1 mg, 118 μmol). 
Rf value: 0.48 (hexane : EtOAc = 10 : 1). 
1H-NMR (400 MHz, CDCl3) δ –0.09 (3H, s, SiMe), –0.07 (3H, s, SiMe), 0.76 (3H, d, J=6.8 Hz, 
Me-14), 0.80 (9H, s, SitBu), 1.31 (3H, d, J=2.0 Hz, Me-14), 1.55 (3H, s, Me-12), 1.58 (3H, d, J=6.8 
Hz, Me-18), 1.73 (3H, s, Me-16), 2.30 (1H, dd, J=14.4, 7.2 Hz, H-9), 2.41 (1H, dd, J=14.4, 8.0 Hz, 
H-9'), 2.60 (1H, d, J=4.8 Hz, H-7), 2.62 (1H, dd, J=8.0, 2.0 Hz, H-14), 2.65 (1H, d, J=4.8 Hz, H-7'), 
3.63 (1H, d, J=8.0 Hz, H-15), 5.21 (1H, d, J=8.0 Hz, H-13), 5.31 (1H, q, J=6.8 Hz, H-17), 5.45 (1H, 
ddd, J=14.6, 8.0, 7.2 Hz, H-10), 6.50 (1H, d, J=14.6 Hz, H-11). 
 
 
Me
MeMeMe Me
OTBS OMe
OH
89  
(4E,6Z,8R,9R,10E)-9-(((1,1-Dimethylethyl)dimethylsilyl)oxy)-2-Methoxy-2,6,8,10-
tetramethyldodeca-4,6,10-triene-1-ol (89) 
 
 A solution of triene 88 (43.1 mg, 118 μmol) in methanol (800 μl) was added camphorsulfonic 
acid (1.4 mg, 5.9 μmol) at 0 °C under argon atmosphere, and stirred for 1 hour. Triethylamine (5 μl, 
36.5 μmol) was added and the resulting mixture was concentrated to afford the residue which was 
purified on silica gel column chromatography (BW820-MH 10 g, hexane : EtOAc = 8 : 1) to 
primary alchol 89 (38.0 mg, 95.8 μmol, 67% in 2 steps). 
 
Rf value: 0.09 (hexane : EtOAc = 8 : 1). 
[α]D25 –2.93° (c 1.00, CH2Cl2). 
1H-NMR (400 MHz, CDCl3) δ –0.09 (3H, s, SiMe), –0.07 (3H, s, SiMe), 0.75 (3H, d, J=6.7 Hz, 
Me-14), 0.80 (9H, s, SitBu), 1.12 (3H, s, Me-8), 1.55 (3H, s, Me-12), 1.58 (3H, d, J=6.7 Hz, Me-18), 
1.73 (3H, s, Me-16), 1.86 (1H, t, J=6.0 Hz, OH-7), 2.22-2.41 (2H, m, H-9), 2.61 (1H, ddq, J=9.6, 
8.0, 6.7 Hz, H-14), 3.26 (3H, s, OMe), 3.42 (1H, dd, J=11.2, 6.1 Hz, H-7), 3.48 (1H, dd, J=11.2, 6.1 
Hz, H-7'), 3.62 (1H, d, J=8.0 Hz, H-15), 5.19 (1H, d, J=9.6 Hz, H-13), 5.32 (1H, q, J=6.6 Hz, H-17), 
5.46 (1H, dt, J=15.5, 7.7 Hz, H-10), 6.09 (1H, d, J=15.5 Hz, H-11). 
13C-NMR (100 MHz, CDCl3) δ –5.1, –4.8, 10.8, 10.8, 12.9, 13.1, 17.5, 18.1, 19.0, 19.1, 25.7, 37.2, 
38.5, 38.5, 49.3, 49.4, 66.8, 66.8, 77.2, 77.3, 77.4, 83.6, 83.6, 121.1, 121.3, 132.9, 132.9, 136.1, 
136.2, 137.2, 138.7, 138.7. 
 
 
CHOMe
MeMeMe Me
OTBS MeO
90   
(4E,6Z,8R,9R,10E)-9-(((1,1-Dimethylethyl)dimethylsilyl)oxy)-2-methoxy-2,6,8,10-
tetramethyldodeca-4,6,10-trienal (90) 
 
 A mixture of primary alchol 89 (225 mg, 566 μmol) and triethylamine (1.58 ml, 11.3 mmol) in 
dimethoxyethane (3.9 ml) was added sulfur trioxide pyridine complex (895 mg, 5.62 mmol) at room 
temperature under argon atmosphere, and the resulting mixture was stirred for 30 minutes. Toluene 
(12 ml) and water (4.0 ml) were added, and the layer was separated. The aqueous solution was 
extracted with toluene (12 ml) and the combined organic extracts were washed twice with brine (3.0 
ml×2). The organic extracts were concentrated to afford the residue which was purified on silica gel 
column chromatography (BW820-MH 28 g, hexane : EtOAc = 25 : 1) to aldehyde 90 (211 mg, 535 
μmol, 94%). 
 
－95－ 
Rf value: 0.48 (hexane : EtOAc = 10 : 1).  
[α]D25 –3.30° (c 1.11, CH2Cl2). 
HRFAB-MS (m/z): 393.3827 [M-H]+; calcd for C23H41O3Si1: 393.2825.  
1H-NMR (400 MHz, CDCl3): (the value in bracket is data of the isomer at C8 position): δ –0.09 (3H, 
s, SiMe), –0.07 (3H, s, SiMe), 0.75 (3H, d, J=6.9 Hz, Me-14), 0.80 (9H, s, SitBu), 1.21 [1.22] (3H, s, 
Me-8), 1.55 (3H, s, Me-12), 1.58 (3H, d, J=6.4 Hz, Me-18), 1.71 (3H, s, Me-16), 2.33-2.52 (2H, m, 
H-9), 2.59 (1H, ddq, J=10.1, 8.0, 6.9 Hz, H-14), 3.32 (3H, s, OMe), 3.62 (1H, d, J=8.0 Hz, H-15), 
5.20 (1H, d, J=10.1 Hz, H-13), 5.31 (1H, q, J=6.4 Hz, H-17), 5.41 (1H, dt, J=17.9, 7.5 Hz, H-10), 
6.09 (1H, d, J=17.9 Hz, H-11), 9.58 [9.59] (1H, s, H-7). 
13C-NMR (100 MHz, CDCl3) δ –5.1, –4.8, 10.8 [10.8], 12.9 [13.0], 17.4, 17.5 [17.5], 18.1, 25.7, 
37.3, 38.0 [38.2], 51.9 [51.9], 82.4 [82.4], 83.5 [83.6], 118.9, 121.3 [121.3], 132.7, 136.7 [136.7], 
137.1, 139.5 [139.6], 205.0 [205.1]. 
IR (KBr) 3031, 2956, 2929, 2856, 2829, 2800, 2701, 1737, 1471, 1461, 1247, 1079, 1056, 860, 836, 
773.  
 
 
OMe OMe
Me
O
Me
MeMeMe Me
OTBS OMe
91  
2-((1E,5E,7E,9R,10R,11E)-10(((1,1-Dimethylethyl)dimethylsilyl)oxy)-3-methoxy-3,7,9,11-
tetramethyltrideca-1,5,7,11-tetraenyl)-6-methoxy-3,5-dimethyl-4H-pyran-4-one (91) 
 
 A solution of phosphine 79 (183 mg, 600 μmol) in tetrahydrofuran (5.7 ml) was added 1.0M 
lithiumbis(trimethylsilyl)amide in tetrahydrofuran (576 μl, 576 μmol) at –78 °C under argon 
atmosphere, and the resulting mixture was stirred at –60 °C for 1 hour. Aldehyde 90 (189 mg, 480 
μmol) which was dissolved in tetrahydrofuran (3.7 ml) was added, and the mixture was stirred for 1 
hour. The mixture was warmed to 0 °C over 2.5 hours and stirred for 2 hours. Acetic acid was added 
and the resulting mixture was concentrated to afford the residue which was purified on silica gel 
column chromatography (BW820-MH 30 g, hexane : EtOAc = 3 : 1) to γ-pyrone 91 (250 mg, 459 
μmol, 96%). 
 
Rf value: 0.10 (hexane : EtOAc = 4 : 1). 
[α]D23 –0.99° (c 1.15, CH2Cl2). 
1H-NMR (400 MHz, CDCl3): (the value in bracket is data of the isomer at C-8 position): δ –0.12 
(3H, s, SiMe), –0.10 (3H, s, SiMe), 0.75 (3H, d, J=6.9 Hz, Me-14), 0.78 [0.79] (9H, s, SitBu), 1.33 
[1.34] (3H, s, Me-8), 1.54 (3H, s, Me-12), 1.58 (3H, d, J=6.7 Hz, Me-18), 1.71 [1.72] (3H, s, Me-2), 
1.87 (3H, s, Me-16), 2.04 (3H, s, Me-4), 2.43 (2H, d, J=7.1 Hz, H-9), 2.60 (1H, m, H-14), 3.24 
[3.26] (3H, s, OMe), 3.62 (1H, d, J=8.3 Hz, H-15), 4.00 (3H, s, OMe-1), 5.19 (1H, d, J=10.1 Hz, H-
13), 5.31 (1H, q, J=6.9 Hz, H-17), 5.41-5.52 (1H, m, H-10), 6.08 [6.10] (1H, d, J=15.2 Hz, H-11), 
6.36 (1H, d, J=16.6 Hz, H-6), 6.48 [6.49] (1H, d, J=16.6, 2.4 Hz, H-7). 
13C-NMR (100 MHz, CDCl3) δ –5.1, –4.8, 6.9, 9.7, 10.8 [10.8], 12.9 [13.1], 17.5 [18.1], 21.9 [22.3], 
25.7, 37.3, 43.4 [43.6], 50.5 [50.6], 55.3 [55.3], 77.2 [77.5], 83.5, 99.6 [99.6], 119.0 [119.0], 119.3 
[119.5], 120.7 [120.8], 121.3 [121.3], 132.8 [132.8], 136.3 [136.4], 137.1 [137.1], 138.9 [139.0], 
140.3 [140.4], 151.3 [151.3], 161.7, 181.0. 
 
 
 
 
 
－96－ 
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76  
2-((1E,5E,7E,9R,10R,11E)-10-Hydroxy-3-methoxy-3,7,9,11-tetramethyltrideca-1,5,7,11-tetraenyl)-
6-methoxy-3,5-dimethyl-4H-pyran-4-one (76) 
 
 A solution of γ-pyrone 91 (31.1 mg, 57.1 μmol) in methanol (1.6 ml) was added campharsulfonic 
acid (13.3 mg, 57.1 μmol) which was dissolved in methanol (400 μl) at room temperature under 
argon atmosphere, and left for 18 hours. Triethylamine was added at 0 °C, and the resulting mixture 
was concentrated to afford the residue which was purified on silica gel column chromatography 
(BW820-MH 9.6 g, hexane : EtOAc = 1 : 1) to secondary alcohol 76 (17.2 mg, 39.9 μmol, 70%). 
 
Rf value: 0.19 (hexane : EtOAc = 1 : 1). 
[α]D25 +3.64° (c 1.28, CH2Cl2). 
HRFAB-MS (m/z): 431.2769 [M+H]+; calcd for C26H39O5: 431.2797.  
1H-NMR (400 MHz, CDCl3): (the value in bracket is data of the isomer at C8 position):  δ 0.81 
(3H, d, J=6.9 Hz, Me-14), 1.35 (3H, s, Me-8), 1.63 (3H, d, J=5.1 Hz, Me-18), 1.64 (3H, s, Me-12), 
1.80 (3H, s, Me-2), 1.87 (3H, s, Me-16), 2.05 (3H, s, Me-4), 2.44 (2H, d, J=7.2 Hz, H-9), 2.69 (1H, 
ddq, J=9.6, 9.1, 6.5 Hz, H-14), 3.25 [3.25] (3H, s, OMe), 3.63 (1H, d, J=9.1 Hz, H-15), 4.00 [4.00] 
(3H, s, OMe-1), 5.26 (1H, d, J=9.6 Hz, H-13), 5.49 (1H, q, J=6.2 Hz, H-17), 5.53-5.63 (1H, m, H-
10), 6.13 [6.14] (1H, d, J=16.3 Hz, H-11), 6.36 (1H, d, J=16.3 Hz, H-6), 6.50 [6.51] (1H, d, J=16.3 
Hz, H-7). 
13C-NMR (100 MHz, CDCl3) δ 6.9, 9.6, 10.5, 13.1 [13.1], 17.4, 22.2 [22.2], 36.8, 43.5 [43.6], 50.5, 
55.3, 77.2 [77.2], 82.8, 99.6, 119.1, 119.5 [119.5], 122.4 [122.5], 123.6, 134.1 [134.1], 135.5 
[135.5], 135.6, 138.0 [138.1], 140.0, 151.2, 161.7, 181.0. 
IR (KBr) 3423, 3029, 2971, 2925, 2863, 2829, 1666, 1631, 1602, 1577, 1465, 1417, 1376, 1336, 
1259, 1168, 968.  
 
 
OMe OMe
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O
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(+)-Actinopyrone A (60)  
2-((2Z,5E,7Z,9R,10R,11E)-10-Hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraenyl)-6-methoxy-
3,5-dimethyl-4H-pyran-4-one, (+)-actinopyrone A (60) 
 
 A mixture of secondary alchol 76 (6.3 mg, 14.6 μmol) and iso-propanol (11 μl, 14.6 μmol) in 
tetrahydrofuran (630 μl) was added 0.1M samarium iodide in tetrahydrofuran (438 μl, 43.8 μmol) at 
–78 °C under argon atmosphere, and the resulting mixture was stirred at –20 °C for 30 minutes. Air 
was bubbled, then ethyl acetate (1.0 ml), saturated aqueous sodium bicarbonate (0.5 ml) and water 
(0.5 ml) was added, and the layer was separated. The aqueous solution was extracted with ethyl 
acetate (0.5 ml) and the combined organic extracts were concentrated to afford the residue which 
was purified on silica gel column chromatography (BW820-MH 1.3 g, hexane : EtOAc = 1 : 1) to 
(+)-actinopyrone A (60) (4.7 mg, 11.7 μmol, 80%). 
 
 
 
 
－97－ 
Rf value: 0.24 (hexane : EtOAc = 1 : 1). 
synthetic: [α]D25 +31.3 (c 0.43, CH2Cl2) [natural [α]D26 +30.8 (c 0.42, CH2Cl2)]. 
HRFAB-MS (m/z): 401.2673 [M+H]+; calcd for C25H37O4: 401.2692.  
1H-NMR (400 MHz, CDCl3) δ 0.81 (3H, d, J=6.9 Hz, Me-14), 1.63 (3H, d, J=6.0 Hz, Me-17), 1.64 
(3H, s, Me-12), 1.67 (1H, br, OH-15), 1.73 (3H, s, Me-16), 1.81 (3H, s, Me-8), 1.84 (3H, s, Me-2), 
1.96 (3H, s, Me-4), 2.68 (1H, ddq, J=9.6, 9.1, 6.9 Hz, H-14), 2.80 (2H, d, J=6.9 Hz, H-9), 3.31 (2H, 
d, J=7.3 Hz, H-6), 3.63 (1H, d, J=9.1 Hz, H-15), 3.92 (3H, s, OMe), 5.24 (1H, d, J=9.6 Hz, H-13), 
5.26 (1H, t, J=7.3 Hz, H-7), 5.49 (1H, q, J=6.0 Hz, H-17), 5.56 (1H, dt, J=15.5, 6.9 Hz, H-10), 6.10 
(1H, d, J=15.5 Hz, H-11). 
13C-NMR (100 MHz, CDCl3) δ 6.9, 9.9, 10.5, 13.1, 13.2, 16.6, 17.4, 30.0, 36.9, 42.9, 55.2, 82.8, 
99.3, 118.0, 118.1, 123.6, 125.6, 133.8, 135.57, 135.61, 136.4, 138.0, 156.9, 162.1, 181.0. 
IR (KBr) 3407, 3023, 2958, 2923, 2863, 1666, 1587, 1463, 1378, 1326, 1251, 1164. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
－98－ 
 
1H-NMR spectrum of 61 (400MHz, CDCl3) 
 
IR spectrum of 61 (100MHz, CDCl3) 
 
－99－ 
 
1H-NMR spectrum of α-pyrone (400MHz, CDCl3) 
 
 
IR spectrum ofα-pyrone (100MHz, CDCl3) 
 
 
－100－ 
 
1H-NMR spectrum of 82 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 82 (100MHz, CDCl3) 
－101－ 
 
1H-NMR spectrum of 78 (400MHz, CDCl3) 
 
 
IR spectrum of 78 
－102－ 
 
1H-NMR spectrum of 84 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 84 (100MHz, CDCl3) 
 
 
 
－103－ 
 
1H-NMR spectrum of 79 (400MHz, CDCl3) 
 
 
IR spectrum of 79 
 
－104－ 
 
1H-NMR spectrum of 86 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 86 (100MHz, CDCl3) 
 
－105－ 
 
1H-NMR spectrum of 87 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 87 (100MHz, CDCl3) 
－106－ 
 
1H-NMR spectrum of 71 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 71 (100MHz, CDCl3) 
－107－ 
 
1H-NMR spectrum of 88 (400MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
－108－ 
 
1H-NMR spectrum of 89 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 89 (100MHz, CDCl3) 
 
－109－ 
 
1H-NMR spectrum of 90 (400MHz, CDCl3) 
 
 
IR spectrum of 90 
 
 
 
－110－ 
  
1H-NMR spectrum of 91 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 91 (100MHz, CDCl3) 
－111－ 
 
1H-NMR spectrum of 76 (400MHz, CDCl3) 
 
 
IR spectrum of 76 
 
－112－ 
 
1H-NMR spectrum of synthetic actinopyrone A (60) (400MHz, CDCl3) 
 
 
13C-NMR spectrum of synthetic actinopyrone A (60) (100MHz, CDCl3) 
－113－ 
 
IR spectrum of synthetic actinopyrone A (60) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
－114－ 
 
1H-NMR spectrum of Z-isomer actinopyrone A (60) (400MHz, CDCl3) 
 
 
13C-NMR spectrum of Z-isomer actinopyrone A (60) (100MHz, CDCl3) 
－115－ 
 
1H-NMR spectrum of natural actinopyrone A (60) (400MHz, CDCl3) 
 
 
1H-NMR spectrum of natural actinopyrone A (60) (400MHz, CDCl3) 
 
－116－ 
3. Total Synthesis of TMC-264, an Inhibitor of IL-4 Signal Transduction 
 
Me
OH
OH
OMe
105 3-Methoxy-5-methylbenzene-1,2-diol (105) 
 
 A solution of 1,2,3-trimethoxy-5-methylbenzene (102) (17.0 ml, 101 mmol) in dichloromethane 
(170 ml) was added 1.0M solution of boron tribromide in dichloromethane (101 ml, 101 mmol) at 
0 °C under argon atmosphere, and stirred for 1 hour. The mixture was added 3.0M aqueous sodium 
hydroxide, and warmed to room temperature. After addition of 1.0M aqueous hyrdrochloride, the 
layers were separated, and the aqueous solution was extracted three times with chloroform.  The 
combined organic extracts were concentrated to afford the residue which was purified on silica gel 
column chromatography (BW820-MH 200 g, hexane : EtOAc = 2 : 1) to diol 105 (13.4 g, 86.9 
mmol, 87%). 
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106 3-Bromo-6-methoxy-4-methylbenzene-1,2-diol (106) 
 
 A solution of diol 105 (512 mg, 3.32 mmol) in carbontetrachloride (52 ml) was added N-
bromosuccinimide (611 mg, 3.49 mmol) at 0 °C under argon atmosphere, and stirred for 24 hours. 
Water (30 ml), 1.0M aqueous hyrdrochloride (16 ml) and carbontetrachloride (90 ml) was added. 
The layers were separated, and the aqueous solution was extracted with carbontetrachloride. The 
combined extracts were concentrated to afford the residue which was recrystalized by ethyl acetate 
to afford bromide 106 (610 mg, 2.62 mmol, 80%). 
 
Rf value: 0.41 (CHCl3 : EtOAc = 4 : 1). 
plates recrystallized from EtOAc; m.p. 142.0 °C (decomposed). 
HRFAB-MS (m/z): 231.9760 [M]; calcd for C8H9O3Br: 231.9735. 
1H-NMR (400MHz, CDCl3): δ 2.33 (3H, s, Me-1), 3.86 (3H, s, OMe-3), 5.36 (1H, s, OH-4), 5.61 
(1H, s, OH-4a), 6.43 (1H, s, H-2). 
13C-NMR (100MHz, CDCl3): δ 22.6, 56.2, 104.1, 105.2, 128.6, 131.1, 140.7, 145.9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
－117－ 
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3-Bromo-5-chloro-6-methoxy-4-methylbenzene-1,2-diol (111) 
 
 A solution of bromide 106 (61.4 mg, 263 μmol) in tetrahydrofuran (1.2 ml) was added N-
chlorosuccinimide (42.1 mg, 315 μmol) at room temperature under argon atmosphere, and stirred 
for 2 hours. The resulting mixture was added silica gel (700 mg), and concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 7.0 g, PhMe : 
acetone = 7 : 1) to chloride 111 (42.9 mg, 160 μmol, 61%). 
 
Rf value: 0.29 (hexane : EtOAc = 2 : 1). 
plates recrystallized from EtOAc; m.p. 94.7 °C. 
HRFAB-MS (m/z): 267.9325 [M]; calcd for C8H8O3BrCl: 267.9323. 
1H-NMR (400MHz, CDCl3): δ 2.45 (3H, s, Me-1), 3.91 (3H, s, OMe-3), 5.60-5.76 (2H, br, OH-4, 
OH-4a). 
13C-NMR (100MHz, CDCl3): δ 20.0, 60.9, 107.7, 119.5, 127.1, 135.7, 140.2, 143.0. 
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113  
2-Bromo-4-chloro-5-methoxy-6-(methoxymethoxy)-3-methylphenol (112) 
3-Bromo-5-chloro-6-methoxy-2-(methoxymethoxy)-4-methylphenol (113) 
 
 A mixture of chloride 111 (444 mg, 1.66 mmol) and diisopropylethylamine (870 μl, 4.98 mmol) 
in N,N-dimethylformamide (18 ml) was added 1.0M solution of zinc dichloride in diethylether (1.7 
ml, 1.7 mmol) at 0 °C under argon atmosphere, and stirred for 1.5 hours. The resulting mixture was 
cooled to –40 °C, and added chloro methylmethylether (140 μl, 1.82 mmol). The mixture was 
stirred for 1.5 hours and added methanol (1,8 ml), then concentrated to afford the residue which was 
purified on silica gel column chromatography (BW820-MH 25 g, CHCl3 : hexane : EtOAc = 40 : 
20 : 1) to desired coumpound 112 (427 mg, 1.37 mmol, 83%) and undesired coumpound 113 (66.0 
mg, 212 μmol, 13%). 
 
Rf value of 112: 0.30 (hexane : EtOAc = 5 : 1). 
needles recrystallized from MeOH; m.p. 113.8 °C. 
HRFAB-MS (m/z): 309.9617 [M]; calcd for C10H12O4BrCl: 309.9607. 
1H-NMR (400MHz, CDCl3): δ 2.49 (3H, s, Me-1), 3.60 (3H, s, CH2OMe), 3.86 (3H, s, OMe-3), 
5.14 (2H, s, CH2OMe), 6.88 (1H, s, OH-4a). 
13C-NMR (100MHz, CDCl3): δ 20.6, 57.7, 60.9, 99.8, 108.0, 119.9, 132.6, 137.2, 146.1, 148.5. 
 
Rf value of 113: 0.28 (hexane : EtOAc = 5 : 1). 
needles recrystallized from hexane; m.p. 104.6 °C. 
HRFAB-MS (m/z): 309.9628 [M]; calcd for C10H12O4BrCl: 309.9607. 
1H-NMR (400MHz, CDCl3): δ 2.47 (3H, s, Me-1), 3.65 (3H, s, CH2OMe), 3.91 (3H, s, OMe-3), 
5.12 (2H, s, CH2OMe), 6.90 (1H, s, OH-4). 
13C-NMR (100MHz, CDCl3): δ 20.4, 57.8, 60.7, 99.8, 114.9, 124.7, 127.4, 141.9, 142.3, 144.1. 
－118－ 
MeO Cl
OMe
Br
118 2-Bromo-1-chloro-3,5-dimethoxybenzene (118) 
 
 A solution of 1-chloro-3,5-dimethoxybenzene (104) (2.46 g, 14.3 mmol) in dichloroethane (50 
ml) was added N-bromosuccinimide (2.66 g, 14.9 mmol) under nitrogen atmosphere, and stirred at 
60 °C for 5 hours. The resulting mixture was added silica gel (10 g), and concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 100 g, hexane : 
EtOAc = 6 : 1) to bromide 118 (3.20 g, 12.7 mmol, 90%). 
 
Rf value: 0.34 (hexane : EtOAc = 10 : 1). 
plates recrystallized from EtOAc; m.p. 78.5 °C. 
HRFAB-MS (m/z): 251.9366 [M]; calcd for C8H8O2BrCl: 251.9376. 
1H-NMR (400MHz, CDCl3): δ 3.79 (3H, s, OMe-9), 3.86 (3H, s, OMe-7), 6.38 (1H, s, H-8), 6.64 
(1H, s, H-10). 
13C-NMR (100MHz, CDCl3): δ 55.7, 56.5, 98.4, 103.7, 106.7, 135.8, 157.8, 159.7. 
 
 
MeO Cl
OMe
OH
O
103 2-Chloro-4,6-dimethoxybenzoic acid (103) 
 
 A mixture of 1.00M s-butyl lithium in cyclohexane (640 μl, 640 μmol) and toluene (20 ml) was 
added bromide 118 (153 mg, 610 μmol) in toluene (1.0 ml) at –78 °C under argon atmosphere, then 
the resulting mixture was stirred under carbondioxide atmosphere and warmed to room temperature. 
1.0M aqueous hyrdrochloride (1.0 ml, 1.0 mmol) was added, then the layers were separated, and the 
aqueous solution was extracted three times with ethyl acetate. The combined extracts were 
concentrated to afford the residue which was purified on silica gel column chromatography 
(BW820-MH 5.4 g, hexane : EtOAc = 3 : 4) to benzoic acid 103 (119 mg, 548 μmol, 90%). 
 
Rf value: 0.25 (hexane : EtOAc = 3 : 4). 
plates recrystallized from EtOAc; m.p. 155.0 °C. 
HRFAB-MS (m/z): 216.0168 [M]; calcd for C9H9O4Cl: 216.0189. 
1H-NMR (400MHz, CDCl3): δ 3.82 (3H, s, OMe-9), 3.86 (3H, s, OMe-7), 6.40 (1H, d, J = 2.0Hz, 
H-8), 6.56 (1H, d, J = 2.0Hz, H-10). 
13C-NMR (100MHz, CDCl3): δ 55.7, 56.3, 97.6, 106.6, 115.0, 133.6, 158.8, 162.0, 169.4. 
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Me
O
OMOM
OMe
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Cl
OOMe
MeO Cl
136
MeO Cl
OMe
Cl
O
135  
2-Chloro-4,6-dimethoxybenzoyl chloride (135) 
2-Bromo-4-chloro-5-methoxy-6-(methoxymethyl)-3-methylphenyl 2-chloro-4,6-
dimethoxybenzoate (136) 
 
 A mixture of benzoic acid 103 (193 mg, 892 μmol) and N,N-dimethylformamide (5.0 ml, 65.0 
μmol) in dichloromethane (6.0 ml) was added oxalylchloride (230 μl, 2.68 mmol) under argon 
atmosphere. The resulting mixture was left at 40 °C for 5 hours. The mixture was concentrated to 
afford acid chloride 135, and which was dissolved in pyridine (3.0 ml). The solution was added 
desired mono methoxymethyl compound 112 (280 mg, 899 μmol) in pyridine (3.0 ml) at room 
temperature and left at 50 °C for 16 hours. The resulting solution was concentrated to afford the 
residue which was purified on silica gel column chromatography (BW820-MH 9.0 g, hexane : 
EtOAc = 3 : 1) to condensate 136 (372 mg, 729 μmol, 82%). 
 
Spectrum data of 135: 
1H-NMR (400MHz, CDCl3): δ 3.82 (3H, s, OMe), 3.86 (3H, s, OMe), 6.38 (1H, d, J = 2.0Hz, H-8), 
6.52 (1H, d, J = 2.0Hz, H-10). 
13C-NMR (100MHz, CDCl3): δ 55.8, 56.3, 97.6, 106.2, 121.1, 131.3, 157.5, 162.5, 165.4. 
 
Rf value of 136: 0.33 (hexane : EtOAc = 3 : 1). 
plates recrystallized from acetone; m.p. 119.9 °C. 
HRFAB-MS (m/z): 510.9718 [M]; calcd for C19H19O7BrCl2: 510.1131. 
1H-NMR (400MHz, CDCl3): δ 2.55 (3H, s, Me-1), 3.55 (3H, s, CH2OMe), 3.84 (3H, s, OMe), 3.88 
(3H, s, OMe), 3.92 (3H, s, OMe), 5.15 (2H, s, CH2OMe), 6.43 (1H, d, J = 2.0Hz, H-8), 6.59 (1H, d, 
J = 2.0Hz, H-10). 
13C-NMR (100MHz, CDCl3): δ 20.9, 55.7, 56.0, 57.6, 61.1, 97.6, 99.3, 106.6, 114.9, 127.2, 132.8, 
133.9, 141.4, 142.0, 149.6, 159.4, 162.2, 162.4. 
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127  
2-Chloro-3,7,9-trimethoxy-4-(methoxymethoxy)-1-methyl-6H-benzo[c]chromen-6-one (127) 
2-Chloro-4,7-dihydroxy-3,9-dimethoxy-1-methyl-6H-benzo[c]chromen-6-one (141) 
 
 A mixture of condensate 136 (4.5 mg, 8.82 μmol) and bis(1,5-cyclooctadiene)nickel(0) (24.5 mg, 
89.1 μmol) in dimethylformamide (4.5 ml) was added 1.00M dichloroethylaluminum in n-hexane 
(93 μl, 89.1 μmol) at –78 °C under argon atmosphere. The resulting mixture was sonicated at 40 °C 
for 10 hours. The mixture was concentrated and added aqueous hydrochloride and ethyl acetate, 
then extracted three times with ethyl acetate. The combined organic layers were concentrated to 
afford cyclization 127, and which was dissolved in dichloromethane (352 μl). The solution was 
added 1.00M boron tribromide in n-hexane (22.0 μl, 22.0 μmol) at –15 °C and stirred for 20 
minutes. The mixture was added 3.0M aqueous sodium hydroxide, and warmed to room 
temperature. The layers were separated, and the aqueous solution was extracted three times with 
chloroform (2 ml). The combined organic extracts were added silica gel and concentrated to afford 
the residue which was purified on silica gel column chromatography (BW820-MH 0.5 g, PhMe : 
EtOAc = 8 : 1) to diol 141 (2.3 mg, 6.83 μmol, 75%). 
 
Rf value of 141: 0.38 (PhMe : EtOAc = 8 : 1). 
plates recrystallized from MeOH; m.p. 229.7 °C. 
HRFAB-MS (m/z): 33.0516 [M+H]+; calcd for C16H13O6Cl: 336.0400. 
1H-NMR (400MHz, Acetone-d6): δ 2.83 (3H, s, Me-1), 3.96 (3H, s, OMe-3), 4.00 (3H, s, OMe-9), 
6.67 (1H, d, J = 2.0Hz, H-8), 7.32 (1H, d, J = 2.0Hz, H-10), 8.99 (1H, s, OH-4), 11.75 (1H, s, OH-
7). 
13C-NMR (100MHz, Acetone-d6): δ 20.6, 56.4, 61.0, 100.6, 101.1, 106.7, 116.0, 125.0, 127.1, 138.0, 
138.4, 140.8, 145.9, 165.0, 165.8, 167.4. 
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TMC-264 (96)  
2-Chloro-1,7-dihydroxy-3,9-dimethoxy-1-methyl-1H-benzo[c]chromene-4,6-dione, TMC-264 (96) 
 
 A mixture of diol 133 (30.0 mg, 89.1 μmol) and salcomine (62.9 mg, 91.5 μmol) in acetnitrile 
(6.0 ml) was stirred under oxygen atmosphere for 2.5 hours. Methanol was added and the resulting 
mixture was stirred for 0.5 hours. The mixture was decantated and concentrated to afford the 
residue which was purified on silica gel colum column chromatography (BW820-MH 1.6 g, PhMe : 
Acetone : AcOH = 10 : 1 : 0.05) to racemic TMC-264 (96) (18.2 mg, 51.6 μmol, 58%). 
 
Rf value: 0.38 (PhMe : EtOAc = 8 : 1). 
HRFAB-MS (m/z): 353.0430 [M+H]+; calcd for C16H14O7Cl: 352.0350. 
1H-NMR (400MHz, CDCl3): δ 1.94 (3H, s, Me-1), 2.76 (1H, s, OH-1), 3.92 (3H, s, OMe-3), 3.97 
(3H, s, OMe-9), 6.66 (1H, d, J = 2.0Hz, H-8), 7.32 (1H, d, J = 2.0Hz, H-10), 11.34 (1H, s, OH-7). 
13C-NMR (100MHz, CDCl3): δ 29.5, 55.9, 60.5, 72.5, 101.5, 103.3, 107.0, 128.3, 134.3, 141.8, 
144.5, 146.8, 163.6, 164.8, 166.8, 171.8. 
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1H-NMR spectrum of 106 (400MHz, CDCl3) 
 
 
NOE spectrum of 106 (400MHz, CDCl3) 
 
－123－ 
 
1H-NMR spectrum of 111 (400MHz, CDCl3) 
 
13C-NMR spectrum of 111 (100MHz, CDCl3) 
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1H-NMR spectrum of 112 (400MHz, CDCl3) 
 
 
 
1H-NMR spectrum of 112 (400MHz, CDCl3) 
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1H-NMR spectrum of 113 (400MHz, CDCl3) 
 
 
NOE spectrum of 113 (400MHz, CDCl3) 
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1H-NMR spectrum of 118 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 118 (100MHz, CDCl3) 
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1H-NMR spectrum of 103 (400MHz, CDCl3) 
 
 
IR spectrum of 103  
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1H-NMR spectrum of 135 (400MHz, CDCl3) 
 
 
IR spectrum of 135  
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1H-NMR spectrum of 136 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 136 (100MHz, CDCl3) 
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1H-NMR spectrum of 141 (400MHz, CDCl3) 
 
 
13C-NMR spectrum of 141 (100MHz, CDCl3) 
 
－131－ 
 
1H-NMR spectrum of TMC-264 (96) (400MHz, CDCl3) 
 
 
1H-NMR spectrum of TMC-264 (96) (400MHz, CDCl3) 
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13C-NMR spectrum of TMC-264 (96) (100MHz, CDCl3) 
 
 
MASS spectrum of TMC-264 (96)  
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IR spectrum of TMC-264 (96)  
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